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Aim: The main aim of this thesis was to explore the contemporary outcomes of pancreatic 
surgery and treatment of pancreatic ductal adenocarcinoma in Norway seen in light of the 
centralization process and the volume-outcome relationship.  
Methods: We analysed three complete national patient cohorts using prospectively gathered 
data from national medical quality registries. The inclusion criteria were either a having a 
pancreatoduodenectomy (Paper I and II) or being diagnosed with pancreatic ductal 
adenocarcinoma (Paper III). The main studied outcomes were short-term morbidity and 
mortality, and for paper III provision of tumour-directed treatment and survival.  
Results: In paper I we found that the national in-hospital mortality and 90-day mortality after 
pancreatoduodenectomy were 2% and 4%, respectively, and 14% of patients had a 
relaparotomy within 30 days. High age, male gender and relaparotomy were independent 
predictors of 90-day mortality, whereas Regional Health Authority where treated was not. In 
paper II we showed that patients who had a pancreatoduodenectomy at the medium/low-
volume units had similar short-term outcomes to patients treated at the sole high-volume unit 
(>40 PDs a year). For patients diagnosed with pancreatic ductal adenocarcinoma between 
2004-2018 (paper III), resection rates (p<0.001) and use of perioperative chemotherapy 
(p<0.001) increased over time, and survival after resection improved with a HR (95% CI) for 
death of 0.65 (0.57-0.76) between late and early study period. For non-resected patients, 
provision of palliative chemotherapy increased over time (p<0.001). Still, four in ten patients 
did not receive any tumour-directed treatment. 
Conclusions: The postoperative outcomes after pancreatoduodenectomy in Norway are 
beneficial and the current level of centralization of surgery seems just. Although more 
patients with pancreatic ductal adenocarcinoma currently reach resection and the survival 
prospects for this subgroup are slightly improving, no sizeable improvement was seen for this 
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DP  Distal pancreatectomy 
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1 INTRODUCTION  
 
1.1 A century of pancreatic surgery and a century of despair 
Already about 300 years B.C. a Greek anatomist named Eudemos stated on the pancreas: 
“From this gland a fluid similar to saliva runs into the intestine, intended for the improvement 
of digestion”. The more renowned anatomist and surgeon for the roman gladiators, Galen 
(129 A.D. to 216 A.D.) some four hundred years later disregarded the pancreas as merely a 
“fatty cushion for the protection of the mesenteric vessels”. Consequently, the organ did not 
receive attention from the medieval era anatomists and physiologists, and this misperception 
stood rather undisputed up until the 17th century. It was not until its endocrine and exocrine 
secretory functions were (re)discovered and further depicted that the pancreas became subject 
of much attention from physicians and surgeons, and recognized as a potential seat of disease. 
(1) 
The close and complex anatomical relations between the pancreas and its neighbouring organs 
and vessels probably did not make it a tempting goal of major resections in the early eras of 
abdominal surgery. Still, the two-stage and later one-stage pancreatoduodenectomy was 
developed already early in 20th century by courageous surgical pioneers like Codivilla, 
Kausch and Whipple. (1-3) Both morbidity and perioperative mortality rates were initially 
discouraging, and one can only suspect some publication bias from early attempts. 
Nevertheless, perioperative survival was obtained for some patients who later died from 
cancer recurrence. When reading these early reports a century of years, but light-years in 
terms of medical knowledge and surgical progress later, one cannot help but conclude that 
nothing much has really changed. The battles accompanying pancreatic resections are still the 
same. Anastomoses to the pancreas, however sophisticatedly fashioned, still tend to leak. 
Even if all else is well, the postoperative delayed emptying of the stomach remains a common 
complaint. And, although the perioperative mortality has declined tremendously, the 
prospects of long-term survival from resected pancreatic ductal adenocarcinoma remain 
gloomy.  
The present thesis will explore key elements pertaining to safety and quality of pancreatic 
surgery in a modern, high resource health care system in a country with a geography and 
demography seemingly unsuited for centralization of health care services. 
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1.2 Anatomy of the pancreas and its adjacent organs and vessels  
The pancreatic gland is from an embryological point of view considered a “pseudo-
retroperitoneal” organ. It is located behind the free abdominal cavity, but in front of the true 
retroperitoneal space. It is covered ventrally by the stomach, the transverse colon and the 
gastrocolic ligament. The head is attached to and covered laterally by the duodenum, and the 
tail extends to the hilum of the spleen. The head and body rests dorsally on the vena cava 
inferior and abdominal aorta, and the superior mesenteric artery and superior mesenteric vein, 
splenic vein and portal vein all run in close proximity. These above-mentioned organs and 
vessels must be either carefully mobilized, exposed or resected when obtaining surgical 
access to the pancreas.  
 
Figure 1: Anatomy of the pancreas and its adjacent organs and vessels. (From www.netterimages.com) 
 
Surgical resection of the pancreas is largely dominated by two entities: Resection of the 
pancreatic head and neck (pancreatoduodenectomy, aka Whipple procedure) constituting 
about 70% of procedures, and resection of pancreatic body and tail (distal or subtotal 
pancreatectomy) which represents about 20-25%. In addition, but in a far lower scale, total 
 Superior mesenteric artery and vein 
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pancreatectomies (or total pancreatoduodenectomies), central pancreatectomies and 
enucleations are also performed. 
1.2.1 Pancreatoduodenectomy (Whipple procedure) 
In a classic Whipple procedure (see figure 
2), the pancreatic head and neck are removed 
together with the duodenum, the common 
bile duct (ductus choledochus) and the most 
distal part of the stomach. The reconstruction 
is most commonly comprised of three 
anastomoses, a pancreatico-jejunostomy, a 
hepatico-jejunostomy and a gastro-
jejunostomy. Variants of the reconstruction 
exist, including the pylorus-preserving 
procedure where the gastro-jejunostomy is 
replaced by a duodeno-jejunostomy, and the 
Roux-en-Y variant where the end-to-side 
gastro-jejunostomy is replaced by an end-to-
end gastrojejunostomy and a distal small 
bowel anastomosis.  
In all forms, a pancreatoduodenectomy is 
considered a technically challenging 
procedure. Mini-invasive access 
pancreatoduodenectomy, either by standard 
laparoscopy or robot-assisted, is increasingly 
reported. So far, studies have failed to prove 
superior outcomes compared to open access 
surgery besides a slightly shorter length-of-
stay. (4) A recent national Dutch RCT set out 
to compare short-term outcomes after mini-
invasive and open pancreatoduodenectomy 
but was pre-emptively haltered due to higher 
mortality in the mini-invasive access group. 
(5) As with all other minimally invasive 
Figure 2: Pancreatoduodenectomy, classic Whipple 
procedure (From www.thesurgeonscollective.com.au) 
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procedures, we will probably see further implementation despite lack of randomized data to 
support it. 
1.2.2 Distal pancreatectomy 
In a distal (or subtotal) pancreatectomy, the tail (and body) of the pancreas is removed (see 
figure 3). The cut-end of the pancreatic gland and duct (head and neck) is left closed, usually 
by surgical staplers or sutures. No anastomosis is fashioned. Depending on which type of 
neoplasia that is suspected, a lymph node toilette and splenectomy may be warranted. A distal 
pancreatectomy is regarded as a far less complicated procedure than a 
pancreatoduodenectomy, and mini-invasive techniques has gained worldwide acceptance, 
partly also for pancreatic adenocarcinoma. Beneficial short-term outcomes are documented 
(6-8), but studies on long-term oncological outcomes are awaited.  
 
Figure 3: Distal pancreatectomy (From www.thesurgeonscollective.com.au) 
 
1.2.3 Concomitant vascular and multi-visceral resection 
Supported by the improved postoperative outcomes from major pancreatic resection during 
the last decades, and in the pursuit of expanding resectability criteria (and subsequently 
survival), concomitant resection and reconstruction of major mesenteric vessels are 
increasingly performed. The relative safety and efficacy of venous reconstruction techniques 
have been demonstrated (9, 10) while reconstruction of the mesenteric arteries is more prone 
to grave complications and are also of more debatable oncological value. (11) 
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Resection of neighbouring organs (multi-visceral resection) due to either direct tumour 
involvement in organs or essential vessels necessitating organ resection is most commonly 
comprised of partial resection of either the transverse colon, small bowel or stomach. An 
associated increase of both morbidity and mortality is reported in the literature (12, 13) but it 
may be feasible for selected, fit patients to enable pancreatic resection at all. (13) 
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1.3 Indications for pancreatic resection  
Formal pancreatic resections are almost exclusively performed for confirmed or suspected 










A national population-based study from Sweden (14) and a recent single centre series from 
Norway covering a larger time cohort (15) confirmed similar distributions. Notably, 
pancreatic ductal adenocarcinoma (i.e., “true” pancreatic cancer) constitutes less than half of 
the specimens. A national cohort study from Norway covering all distal pancreatic resections 
between 2012 and 2016 (Figure 4) showed that more than 90% were performed on suspicion 
of either malignant or premalignant disease. (16) 
 
Specimens n    (%) 
Any malignancy 324 (82) 
PDAC 161 (41) 
CBD cancer 58 (15) 
Duodenal cancer 36 (9) 
Ampulla cancer 30 (8) 
Other malignancies 39 (10) 
Benign disease 69 (18) 
IPMN 25 (6) 
Pancreatitis 11 (3) 
Other 33 (8) 
Table 1: Histopathology distribution in pancreatoduodenectomy specimens in Norway 2015-2016 (n=393). PDAC: 
Pancreatic ductal adenocarcinoma. CBD: Common bile duct. IPMN: Intraductal papillary mucinous dysplasia. 
Data extracted from supplementary analyses in paper II (see chapter 4.2.1) 
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1.3.1 Pancreatic ductal adenocarcinoma  
Pancreatic cancer, or pancreatic ductal adenocarcinoma (PDAC), is the most common 
indication for pancreatic resection. This malignancy is renowned for a dismal long-term 
prognosis even in patients with early-stage disease. It is now the fourth leading cancer-related 
cause of death in Norway with a relative 5-year survival (all stages) for males of 9 % (95% CI 
8-11) and for females 11% (95% CI 10-13) (17) As illustrated in the two lowermost panels in 
figure 5, it is predominantly a disease of the elderly with a sharp increase in incidence from 
the fifth and sixth decades of life.   
 
 
Figure 4: Distribution in indication for distal pancreatic resections in Norway 2012-2016 (From “A nationwide cohort study 






Figure 5: Age-standardized incidence (upper left) and mortality rates (upper right) over time and age-specific 
incidence (lower left) and mortality rates (lower right) per 100 000 inhabitants (Norway). Source: NORDCAN, 
https://www-dep.iarc.fr/NORDCAN/english/frame.asp) 
 
Surgical removal of the pancreatic tumour is considered the keystone in treatment with 
curative intent, but more than two thirds of patients present with either locally unresectable or 
metastatic disease, or with other frailty barring them from full treatment. Given the 
distribution in age at time of diagnosis (see figure 5) and extent of surgery, only a subset of 
patients with early-stage disease actually reach resection.  
In addition to radiological screening for metastatic disease, technical resectability of PDAC is 
commonly categorized as primary resectable, borderline resectable or locally advanced 
based on tumour relation to, and involvement of, the portal and superior mesenteric veins and 
root and branches from the coeliac arterial trunk and the superior mesenteric artery. (18) 
Surgery is offered to otherwise fit patients with primary resectable disease, borderline 
 
17 
resectable tumours without radiological progression on neoadjuvant CTx and for selected 
patients with locally advanced disease with radiological tumour regression after neoadjuvant 
CTx (down-staging).  
 
Figure 6: D: duodenum. IVC: inferior vena cava, P: pancreas, SMV: superior mesenteric vein, SMA: superior 
mesenteric artery, LRV: left renal vein. Source: https://drcesarramirez.com/cirug 
 
Chemotherapy is increasingly provided in both neoadjuvant and adjuvant settings. The 
Norwegian guidelines recommend adjuvant chemotherapy for resected patients, and 
neoadjuvant treatment is given for borderline tumours and in attempts to downsize locally 
advanced tumours in selected patients. An adjunctive neoadjuvant regimen for primarily 
resectable disease is currently explored within a pan-Scandinavian randomized controlled trial 
(NorPACT-1). (19) 
A Finnish national cohort study re-examined the surgical specimens from long-term survivors 
after resection for PDAC, excluded almost one in two as non-PDACs, and reported a “true” 5-
year overall survival of 7.2%. (20) A more recent national cohort from the Netherlands 
reported a 5-year overall survival after resection of 16.7%. (21) At the other end of the scale, 
single centre series from tertiary referral units in other countries report 5-year overall survival 
after resected PDAC of up to 30-40%. (22, 23) This discrepancy is probably multifactorial. 
Patient selection most likely differs between expert centre series and population-based 
studies; use of chemotherapy plays an increasingly important role and is unevenly 
implemented. Regardless, there is so far little evidence to suggest that modern treatment 
including radical surgery and extensive chemotherapy in fact results in a substantially higher 
long-term (five-year) survival for resected patients. Time from primary treatment to 
documented recurrence of disease and median overall survival may increase, but “true” 
curation in terms of long-term disease-free survival is still anecdotal to the extent that it is 
haunted by scepticism towards the original histopathological diagnosis. (20) 
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Patients with primary metastatic or recurrent disease in Norway are currently considered for 
palliative treatment in terms of chemotherapy. Palliative radiotherapy is occasionally used for 
localized unresectable disease or for pain relief. 
1.3.2 Cystic lesions of the pancreas 
Asymptomatic cystic lesions of the pancreas are increasingly detected in radiological 
examinations of the abdomen performed for unrelated or vague indications, and often in 
elderly patients. (24) Although originally benign, some of these cystic lesions (mainly 
intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs)) 
hold an inherent potential of malignant transformation to adenocarcinoma. A timely 
identification and resection of a premalignant pancreatic lesion represents a golden 
opportunity to prevent the development of a next to incurable malignancy. Importantly, the 
uncertain individual benefit from such a prophylactic pancreatic resection must be viewed 
against the fact that many of these patients are elderly or otherwise frail and may have other 
more impending threats influencing on their life expectancy. 
 
1.4 The nature and incidence of postoperative complications after pancreatic surgery 
1.4.1 Overall complication burden 
Pancreatic resections carry a heavy complication burden, even in the era of modern surgery 
and modern perioperative management. For pancreatoduodenectomies, about one in three 
patients experience at least one major complication, and 10-15% need a relaparotomy within 
30 days from the index procedure. (25-27) However, the short-term mortality is decreasing, 
with both expert centre series and recent population-based cohorts reporting a short-term 
mortality after pancreatoduodenectomy below 5%. (25, 28, 29) Both morbidity and mortality 
rates following distal resections are far lower, but the development of a postoperative 
pancreatic fistula from the remnant gland is frequent. Occurrence of complications and 
nutritional issues are the most common causes to a prolonged length-of-stay, especially after a 
pancreatoduodenectomy. The median aggregated length-of-stay (see Methods, 3.3.1) after a 
distal pancreatic resection and a pancreatoduodenectomy in Norway is currently 7 and 14 
days, including transfer stays and readmissions within 30 days. (30) 
Even in the absence of postoperative surgical complications, a pancreatic resection holds the 
potential of substantial unavoidable long-term nutritional side effects. Of note, more than one 
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in two patients undergoing a scheduled pancreatic resection meet the GLIM (Global 
Leadership Initiative in Malnutrition (31)) criteria of malnutrition already prior to surgery, as 
shown by Skeie, Tangvik, Nymo et al in a nationwide analysis of data from the Norwegian 
Registry for Gastrointestinal and HPB surgery (NoRGast). (32) After 
pancreatoduodenectomy, a significant permanent weight loss and up to 3-6 months recovery-
time for restored quality of life are expected. (33) Following any formal pancreatic resection, 
both endocrine (34) and exocrine (35) post-resection dysfunction of the pancreas frequently 
occur, necessitating life-long substitution.  
Considering the poor prognosis for resected ductal adenocarcinomas, the uncertain individual 
survival gain from resection of premalignant cysts and the inescapable long-term aftermath 
after resection, keeping short-term complications to a minimum is crucial to be able to justify 
surgery at all. A pancreatic resection is a major undertaking, and the decision to embark on 
surgery must be taken with caution, in particular for the elderly or otherwise frail. The risk of 
doing more harm than good is indeed present. In the words of Donald J. Trump: "Sometimes 
your best investments are the ones you don´t make". 
1.4.2 Postoperative pancreatic fistula (POPF) 
A postoperative pancreatic fistula is a persistent leak of 
pancreatic juice from either the pancreatico-jejunal anastomosis 
(after a pancreatoduodenectomy) or the suture line from the 
pancreatic remnant (after a distal pancreatectomy). It is 
(obviously) a complication unique to pancreatic surgery and also 
the main determinator of short-term outcome. The international 
study group of pancreatic surgery (ISGPS) holds an 
internationally accepted definition of a POPF that is based on the 
clinical consequences following development of a fistula. (36) 
The phenomenon is divided into three clinical entities. Group B 
and C fistulas are often conjointly named clinically relevant 
fistulas (CR POPF). The detrimental potential of a pancreatic 
fistula after a pancreatoduodenectomy is larger than one 
occurring after a distal resection, as the fistula can prohibit the 
healing of all three anastomoses and is more likely to cause late 
haemorrhage due to erosion of the dissected vessels. The most 
broadly accepted risk factors for fistula development are small 
Figure 7: ISGPS definition and grading of POPF. 
Bassi et al, Surgery 2016  
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pancreatic duct size and soft gland texture, as well as having a high body mass index. (37, 38) 
The reported contemporary incidences of a clinically relevant fistula lie about 12-15% for 
pancreatoduodenectomies (25, 39, 40), and for distal resections 19-30%. (6, 7) The invasive 
treatment options for fistulas include percutaneous drainage of fluid collections and 
relaparotomy for either drainage alone, externalization of anastomotic leakage by drains or 
completion pancreatectomy. A timely handling of a fistula is key to prevent sepsis and organ 
failure. In-hospital mortality following a clinically relevant fistula after 
pancreatoduodenectomy has been reported to be about 18%. (39) 
1.4.3 Post-pancreatectomy haemorrhage (PPH) 
A significant post-pancreatectomy haemorrhage is probably the most feared and lethal 
complication following pancreatic surgery. Similar to the fistulas, ISGPS has graded PPH into 
three entities: grade A is an early (within 24 hours after index surgery) mild bleeding with no 
clinical consequences, grade B is either an early, severe bleeding or a late, mild bleeding and 
grade C is a late, severe bleeding. (6) Bleedings may origin from either the anastomoses or 
from significant vessels that are divided, dissected or reconstructed during the resection and 
occur more frequently in the presence of a pancreatic fistula. Interventional radiographical 
procedures (angiographic coiling or stenting), endoscopic intervention and relaparotomy are 
the invasive treatment options for a PPH. The reported incidence of PPH grade B or C ranges 
from 6.8% to 7.3% (40-42) after a standard pancreatoduodenectomy but may occur as 
frequent as in 14.2% of procedures if a concomitant venous resection is performed. (42) 
Mortality following a late PPH can be as high as 21%. (43)  
1.4.4 Failure-to-rescue (FTR) 
FTR is a quality metric used to measure the ability to prevent mortality after complications 
following medical treatment and is expressed as a ratio of fatalities divided by the number of 
patients with complications. It is gaining popularity worldwide and is considered the "new kid 
on the block" in evaluating and comparing quality of care between units. (44, 45) Up to date, 
no consensus definition of complication exists (severity, excluding/including non-surgical 
complications etc.), and this precludes comparison of FTR-rates across published series. 
Complex surgical procedures with a high complication load, like pancreatic resections, are 
especially suited for this quality metric. A timely and correctly chosen re-intervention for 
either a fistula or haemorrhage demands competent surgical personnel including ward staff, 
interventional radiology service and advanced ICU support available around the clock. 
Divergence in this ability to rescue patients from deteriorating from complications has been 
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proposed as a key reason as to why high-volume specialized HPB units in numerous 
publications are able to obtain lower mortality rates than low volume units, and a more 
important factor than the occurrence of complications in itself. (46, 47) A recent international 
multicentre benchmarking of acceptable outcomes after pancreatoduodenectomy included all 
complications with Clavien-Dindo grade >2 and recommended a cut-off for an acceptable rate 
of FTR of < 9%. (48) 
 
1.5 Centralization of pancreatic surgery and the volume-outcome effect  
An inverse correlation between hospital surgical caseload and short-term mortality after 
pancreatic surgery has repeatedly been demonstrated in the literature, and this volume-
outcome effect is now a broadly accepted paradigm worldwide. (49, 50) For malignant 
disease, the diagnostic work-up and surgical and oncological treatment options available are 
also of increasing complexity and demand a multi-disciplinary approach. (51) An optimal 
handling of postoperative complications illustrated by low FTR rates contribute significantly 
to the superior short-term mortality rates documented in units with a higher case load (46), 
and the hospital academic status is possibly also a part of the picture. (52, 53) Together, this 
has led to a call for centralization of all pancreatic surgery to dedicated high-volume HPB 
units. (54) This process has been gradually implemented in the UK, the Netherlands and 
Scandinavia throughout the last 10-20 years (55), while other large western countries such as 
France, Germany and the US are lagging behind.  
Importantly, there is no clear consensus definition of the respective unit volume categories. 
While some use a cut-off in minimum case load for high volume units at 40 PDs a year (27), 
others advocate a lower threshold with 40 pancreatic resections (PD and DP) a year (56) or 
20 PDs a year. (50) One must take cation to this inconsistency when assessing literature on 
the topic.  
Registry data for unselected population-based cohorts naturally constitute the optimal 
background to study the overall quality of care and the concept of centralization, and in 




1.6 The Norwegian medical registries  
1.6.1 Cancer Registry of Norway (CRN) 
The CRN was established in 1951 and has since collected data for all new confirmed 
malignancies in the Norwegian population. It is one of the world’s oldest existing national 
cancer registries. Direct reporting from pathology departments, clinicians and death 
certificates to CRN is compulsory, and hence coverage rates for diagnoses are considered 
complete. (57) Epidemiological data on incidence and survival is published annually, and 
numerous national and international cancer research projects have sprung out from the CRN 
database. A dedicated sub-registry for pancreatic cancer has recently been established and is 
expected to publish the first annual report by 2021.  
1.6.2 The Norwegian Patient Registry (NPR) 
The NPR has gathered patient level data for all admissions and procedure- and diagnosis 
codes registered in Norwegian hospitals since 2008. The Norwegian hospitals are reimbursed 
based on this coding, and data is considered to be complete from 2010. The accuracy in 
cancer diagnosis codes is in relatively high accordance with data from the CRN (58), but the 
quality of surgical procedure codes, especially for major resections, is considered to be very 
high due to the reimbursement practice. 
1.6.3 The Norwegian Registry for Gastrointestinal and HPB surgery (NoRGast) 
NoRGast was funded in 2014 as a nationwide complication registry for major abdominal 
resections and granted status as a national medical quality registry in 2015. (59) Core data on 
patient case mix, procedures and complications within 30 days from index surgery is gathered 
prospectively. An automatic coupling with the National Registry allows for long-term data on 
survival. The overall coverage rate on patient level for 2019 was 70%, but for hepatobiliary 
resections the coverage rate has been high since 2016 and was 94% for pancreatic resections 
in 2019. (60) 
 
1.7 Pancreatic surgery in Norway  
Bakkevold et al published in 1993 a national cohort study of results after radical and palliative 
surgery for pancreatic cancer in Norway. (61) At this time point, altogether 23 separate units 
(university, county and district hospitals) performed surgery for pancreatic cancer. The 30-
day mortality after radical surgery was 11%. During the next decades, a gradual 
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regionalization of pancreatic resections took place. It was initiated not by strict legislations 
from central health governments, but by an understanding and agreement (or so) within the 
clinical societies in the respective regions. In an international perspective, Norway was an 
early adopter of the volume-outcome doctrine in spite of a demography and geography 
unsuited for centralization. During the last decade, formal pancreatic resections in Norway 
have been performed solely in five university hospital units throughout the four autonomous 
Regional Health Authorities (OUS Rikshospitalet, Stavanger University Hospital, Haukeland 
University Hospital, St Olav University Hospital and the University Hospital of North 
Norway, Tromsø). A formal clinical and scientific multi-disciplinary cooperation with 
representation from all five units has been established (Norwegian Gastrointestinal Cancer 
Group, HPB chapter) in collaboration with the Cancer Registry of Norway. Despite the 
completion of this centralization, or regionalization, the inter-unit variation in annual case 
volume for pancreatic resections vary extensively due to large discrepancies in the uptake 
population in the respective regions.  
 
Figure 8: Demographic overview of the regional catchment populations in the Norwegian health regions (Variation 
in use of open and laparoscopic distal pancreatectomy and associated outcome metrics in a universal health care 




Some single-centre series (15, 62, 63) have been published since the paper by Bakkevold et al 
in 1993. (61) NoRGast data have documented that laparoscopy is an established method for 
distal pancreatectomy in all five operating units, and nationally more than one in two DPs are 
currently done laparoscopically. (60) Mini-invasive PD however has not yet been established 
in either of the units. The annual volume of pancreatic resections in Norway is presently 
increasing, and for 2019 altogether 371 formal pancreatic resections were reported to 
Norwegian Patient Registry.  
In association to this PhD project, we published two papers covering a national 5-year cohort 
(2012-2016) of distal pancreatic resections using administrative data from the NPR. (16, 64) 
The population-based procedure incidence of DP (any indication) increased during the study 
period, especially for laparoscopic DP. The 90-day mortality was low (1.9%) and aggregated 
length of stay (for further description see Methods, 3.3.1 and (30)) was lower following 
laparoscopic procedures. (16)  
 
1.8 Summarized rationale behind the thesis 
While excellent outcomes have been reported in trials and patient series from large centres, 
most patients do not participate in trials, nor do they have surgery at expert centres. Even 
large registry cohorts will present selected series if not all (e.g., private sector hospitals) 
participate, and this is presently the reality in most countries. It is highly likely that many of 
the hallmark publications that currently dominate the “knowledge base” on which physicians 
base their clinical practice regarding pancreatic resection on, underestimate the real-life 
burden of complications and that the reported length-of-stays (LoS) do not correctly capture 
transfer stays at local hospital facilities or readmissions in other units. Likewise, intervention 
trials on novel chemotherapy regimens for pancreatic cancer have strict inclusion criteria, 
which limits its relevance to an unselected PDAC population where many patients, even most, 
are too frail for any regimen. 
Population-based, high-quality medical registry data from countries with government-funded 
public health care systems without private sector alternatives are especially suitable sources to 
survey the true image of the complication burden and recovery after surgery. These 
unselected and complete data represent a valuable complement to data derived from 
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intervention studies or expert centre cohorts as the latter show what under optimal conditions 
might be obtained for the few, while the former depicts the real-life prospects for the many.  
To our knowledge, from the publication by Bakkevold in 1993 and up to present date, no 
national Norwegian cohort analysis covering short-term outcomes after pancreatic surgery or 
treatment practice and long-term survival after PDAC in the post-centralization era has been 
published. The large inter-regional unit volume discrepancy also raises the question of 




2 Aims  
2.1 Main aim of the thesis 
We aimed to explore national and regional practice patterns and short-term complication 
burden after pancreatic resection in Norway in the post-centralization era. For pancreatic 
ductal adenocarcinoma, the most common diagnosis leading to a pancreatic resection, we 
investigated patterns in resection rates and provision of chemotherapy, and long-term 
survival.  
 
2.1.1 Paper I 
To assess the contemporary national and regional population-based procedure incidences, 
patient journeys and short-term complication burden following pancreatoduodenectomy after 
long-standing centralization in Norway.  
 
2.1.2 Paper II 
To compare short-term results including procedure-specific complications after 
pancreatoduodenectomy in one high-volume centre with four medium/low volume centres 
(combined). Would a further centralization lead to improved results across the nation, or is the 
current degree of centralization well-balanced? 
 
2.1.3 Paper III 
To examine diagnosis-specific resection rates, use of chemotherapy and long-term survival 
for pancreatic ductal adenocarcinoma in Norway in a fifteen-year cohort (2004-2018). Are the 
improved survival data that lately have been reported from expert centre resection series and 






3.1 Ethical considerations  
From a patient’ perspective, both on individual and group level, the risk of negative effects 
from the conducted data gathering, alignment and analyses seems low. Regarding data 
security and protection, only patient data already available within the Norwegian medical 
registries or electronic patient files were used. No new information on patients was gathered. 
Patient information regarded as backwards identifiable was kept to a minimum. All data were 
gathered, transferred and stored in line with the regulations given by the Regional Research 
Committee, the local and national data protection offices and the Norwegian Health 
Directory. 
A possible positive effect from the results derived from the studies may be a better evidence 
base and raised awareness for the regional and national clinical societies and administrative 
decision makers. From the provision of evidence for practice patterns and both occurrence 
and handling of complications arises a possibility to pinpoint areas for further quality 
improvement. Contemporary, representative data on expected patient journeys can also aid 
directly in shared decision-making between patient and surgeon on whether to embark on 
surgery or not. For pancreatic ductal adenocarcinoma, with an inherent dismal prognosis, and 
cystic lesions with an unknown potential for development of malignant disease, this weighing 
of risk against potential benefits for each individual patient is crucial.  
 
3.2 Data sources and formal approvals  
Paper 1 was conducted in cooperation with the Centre for Clinical Documentation and 
Analyses (SKDE) in Tromsø. SKDE holds a licence from the National Data Protection office 
for use and analyses of data from the National Patient Registry (NPR), and no additional 
application to the Regional Research Committee was required.   
Paper II used data from the Norwegian Registry for Gastrointestinal and HPB surgery 
(NoRGast). All patients entered into the registry have given a written informed consent form 
also allowing for the use of data in research. The Norwegian Health directory granted access 
to local electronic patient files for completing data, and approval for alignment of data across 
centres was given by the National Data Protection Authority. (Reference 17/33320-2). 
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Combining data from the Cancer Registry of Norway and the Norwegian Patient Registry 
formed the data set for paper III. This was approved by separate applications to the Regional 
Research Committee (reference 81594), the Norwegian Health Directory (reference 
20/12868-5), the data protection office at the Arctic University of Norway (reference 611888) 
and Cancer Norway.  
 
3.3 Methodology and study designs 
All three studies were cohort studies of complete national patient cohorts strictly defined by 
either a specific procedure performed (Paper I and II) or a specific diagnosis given (Paper III) 
in a set time period (five-, two- and fifteen-year cohorts). The inclusion criteria and the 
definitions of outcomes were well defined prior to patient-data entry thus minimizing the risk 
of bias. While analyses were performed at a later time point, all datasets were true cohort 
series (i.e., patients were included by a common exposure and analysed by a later occurring 
outcome). STROBE guidelines for reporting observational studies were adhered to where 
applicable. (65) 
3.3.1 Paper I  
Each individual patient journey in a five-year cohort (2012-2016) of all patients who 
underwent a PD was tracked within the NPR to benchmark the contemporary outcomes after 
longstanding centralization of surgery. 
National and regional population-based procedure incidence rates of PD (of any indication) 
was calculated and adjusted for age- and gender composition over time and between the 
regional populations. Concomitant vascular resection was defined by the presence of 
procedure code(s) for any major venous or arterial reconstruction at the same day of the index 
procedure. Code sets signifying vascular suture, ligature or simple angioplasty were not 
included in the definition. No attempt was made to separate venous from arterial procedures 
due to concerns of a low precision level in coding practice. Multi-visceral resections were 
identified in a similar manner using code sets for simultaneous formal resection (more than a 
wedge resection) of either the colon, small bowel or stomach.  
Relaparotomies were identified by a defined set of NCSP procedure codes denoting any 
surgical access to the abdominal cavity from postoperative day one up to 30 days from index 
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surgery. Any relaparotomy in any Norwegian hospital during the set time interval (including 
transfer stays and readmissions in any unit) was included. 
Length-of-stay was assessed by aggregated length of stay (a-LoS) within 30 days, defined by 
the total aggregated number of days the patients were admitted to any hospital unit in 
Norway, including index stay, transfer stay and readmissions. The complete patient journeys 
for the first 30 days after resection were tracked within the NPR. The novel a-LoS concept 
and benchmark data for all major gastrointestinal resections was published by our group in 
2018. (30)  
All fatalities within 180 days after resection and admission status by demise were registered, 
which allowed for calculation of both 30-, 90- and 180-day as well as in-house and index-stay 
mortality rates.  
The search algorithms for relaparotomy, vascular resection and multi-visceral resection were 
validated against EPJ data for all study patients treated at one unit (UNN Tromsø) and found 
to have a complete (100%) accuracy (data not reported). 
3.3.2 Paper II 
Based on the volume-outcome relationship, we hypothesized that patients who had surgery at 
the one very-high volume unit would fare better in terms of short-term morbidity and 
mortality compared to patients treated at the four lower volume units. A two-year complete 
national cohort of PDs (2015-2016) with more granular data on patients, procedures, 
complications and histopathology was assessed. This dataset was based on NoRGast data. 
Due to an incomplete coverage rate in the registry, a search on procedure codes for PD was 
done within the EPJs at the local units by an HPB surgeon to identify any missing patients. 
The dataset was completed on a patient level and extended with granular information on 
vascular reconstruction, POPF and PPH scored according to the ISGPS definitions for all 
patients. (36, 66, 67) Details on histopathology and the patient journeys of patients who died 
within 90 days were also gathered.  
3.3.3 Paper III 
A complete 15-year cohort (2004-2018) of all patients diagnosed with PDAC was assessed 
for trends in treatment and survival. The dataset was drawn from the Cancer Registry of 
Norway, also utilizing their automatic coupling with the National Patient Registry (NPR). 
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A set of procedure codes and/or diagnostic codes within the NPR was used to identify the 
provision of chemotherapy. For non-resected patients, all chemotherapy between date of 
diagnosis and demise was categorized as palliative treatment. For resected patients, the 
relation in time between the dates of codes denoting provision of chemotherapy and the 
pancreatic resection was used to classify in which setting (neoadjuvant, adjuvant or palliative) 
the chemotherapy was provided. As the NPR does not register pharmaceutical data, the 
specific chemotherapy regimens administered were not possible to identify, nor was the 
method deemed to be of necessary accuracy to describe number of or completeness of 
chemotherapy cycles as codes may be registered for follow-up consultations where no therapy 
was administered. 
To assure data quality on both 1) PDAC diagnosis against other related malignancies in non-
resected patients and 2) provision and setting of chemotherapy, a subgroup of 160 patients 
was randomly drawn from the CRN dataset and cross-checked against electronic patient files. 
This revealed a perfect accuracy (100%) for chemotherapy data and only minor adjustments 
were necessary for the identification of non-resected patients with PDAC. (Data not reported) 
Results from this data validation is planned used as part of a future separate scientific 
publication on the use of combined CRN and NPR data. 
 
3.4 Statistics 
For crude description, categorical outcome measures were reported as rates in absolute figures 
with percentages, and incidences as cases per population size per year. Further, continuous 
variables were reported as medians with 95% confidence intervals (CI) or means with 
standard deviation, as fit. Univariate analyses of categorical variables were done by chi-
square or Fisher exact tests and continuous variables were compared by student t-test or 
Kruskal-Wallis test. Comparisons of incidences and rates between regions or over time were 
adjusted for age- and gender composition in the populations. 
Models for binary, logistic multivariable regression analyses were built in a stepwise 
backwards selection manner, and models were tested for significant interactions and adjusted 
for multiple testing by the Bonferroni method (the latter for Paper I, only). Effect measures 
from univariate and multivariate regression analyses were reported in odds ratios with 95% 
CI. Level of significance for all analyses was set to p < 0.050. Survival curves for paper III 
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were drawn by the Kaplan Meyer method and multivariable Cox proportional hazard 
regression models were estimated to present age-adjusted hazard ratios (95% CI) of death (all 
causes) across time periods. Provision of chemotherapy and surgery was treated as time-
varying covariates in all survival analyses in order to avoid immortal time bias. 
For paper I, the study analyses description including variable definitions and algorithms was 
developed by the first (Nymo) and last author (Lassen), while co-author Frank Olsen at the 
Centre for Clinical Documentation and Evaluation (SKDE) performed the actual statistical 
analyses as he was the only one with permission to access the complete NPR dataset. 
Similarly, for paper III the study analyses were described by the first (Nymo) and last author 
(Lassen), but all statistical analyses were conducted by the second author Tor-Åge Myklebust 
at the Cancer Registry of Norway. All statistical analyses in paper II were done by the first 




4 SUMMARIZED RESULTS 
4.1 Paper I 
 
The effect of centralization on short term outcomes of pancreatoduodenectomy in a 
universal health care system 
HPB 2019, 21 (319-327) 
Paper I was an analysis of a five-year national cohort of PDs for all indications, using 
administrative data (NPR) only.  
Altogether 930 procedures were performed between 2012-2016. The incidence of the 
procedure per population increased during the study period (p=0.006). The national rates of 
concomitant vascular resection and multi-visceral resection were 139 (15%) and 44 (5%), 
respectively. After adjusting for age, gender and patients being operated outside their residing 
RHA there was no difference in use of the procedure between the regional populations, with a 
procedure incidence ranging from 3.4-3.8 PDs per 105 inhabitants per year (p=0.929). There 
was, however, a significant difference in the use of concomitant vascular resection ranging 
from 19% in RHA South-East to 8% in RHA West (p for comparison between all four regions 
=0.021).  
 
Figure 9: Trend for incidence of pancreatoduodenectomy performed each year in Norway (black line with 95% CI 





Some 131 patients (14%) underwent a relaparotomy within 30 days, and 34 patients (3.7%) 
died within 90 days (Figure 3). Of these, one in five relaparotomies and two in five deaths 
occurred outside the index unit. In multivariable analyses, being aged 75 years or more (OR 
13.8, CI 4.2-63.0), male gender (OR 3.4, CI 1.5-9.0) and undergoing a relaparotomy within 
30 days (OR 5.9, CI 2.7-12.8) were independent predictors of mortality within 90 days, 
whereas treating RHA or having a concomitant vascular resection were not. 
 
Figure 10:Over-all postoperative mortality for 2012-2016. Rates at 30, 90 and 180 days after surgery are 
marked with black boxes and in-hospital mortality in dotted grey line. 
 
 
Figure 11: Mortality rates stratified by gender (2a), relaparotomy (2b), age group (2c) and treating RHA (2d). 
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4.2 Paper II 
 
Centralizing a national pancreatoduodenectomy service: Striking the right balance 
BJS Open 2020  
In paper II, a two-year cohort of PDs was analysed for procedure-specific and general 
postoperative complications including failure-to-rescue rates. Results from the one high-
volume centre (n procedures = 201) alone serving more than half of the national population 
was compared to outcomes from the other four medium/low-volume units combined (n 
procedures = 193). The high-volume centre had results in line with internationally established 
benchmarked cut-offs for outcome metrics, but of note, so had the medium volume centres. In 
multivariate regression analyses, the 90- day mortality was lower in the medium/low volume 
group (p=0.023) and although not statistically significant, their failure-to-rescue rate was 6 
out of 68 (8.8%) compared to 11 out of 57 (19.2%) in the high-volume unit.  
 
Figure 12: Accordion grade 3 or higher, 90-day mortality and failure-to-rescue after pancreatoduodenectomy 
2015-2016, stratified for high-volume vs medium/low volume units. 
 
Centralization of pancreatic surgery
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High-volume centre (n= 201)
Medium–low-volume units combined (n= 193)
Medium-volume unit
Low-volume unit
a Postoperative complications (Accordion grade 3–6); b 90-day mortality; c failure-to-rescue. Multivariable analysis with high volume as reference (odds
ratio (OR) 1!00): a OR 1!28 (95 per cent c.i. 0!82 to 1!98), P = 0!274; b OR 0!24 (0!07 to 0!82), P = 0!023; c OR 0!49 (0!26 to 1!63), P = 0!243.
and for PDs without concomitant vascular resection, a
lower rate of classical PD (versus pylorus-preserving PD)
and a higher te of any vascular res ction. Most arterial
resections were performed in the high-volume centre (14
of 16); none of these 16 patients died within 90 days.
Postoperative complications
Crude rates of postoperative complications and univariable
comparison between volume categories are presented in
Table 3. Major complications occurred in 125 patients (31!7
per cent). Results from multivariable analyses are presented
in Table 4. When analysing centre volume category as a
predictor of postoperative outcomes, medium–low volume
was a predictor of lower mortality within 90 days (OR 0!24,
95 per cent c.i. 0!07 to 0!82) but of a higher rate of CR
POPF (OR 2!52, 1!43 to 4!43). Medium–low-volume unit
did not independently predict occurrence of any major
complication, relaparotomy or PPH grade B/C. Impor-
tantly, variation in the use of vascular resection between
the volume categories was adjusted for.
Failure-to-rescue
Detailed patient data for all patients who died within
90 days are shown in Table 5. All but four of the patients
who died within 90 days experienced at least one major
surgical complication within 30 days: CR POPF (8 of 17),
PPH grade B/C (6 of 17) and relaparotomy (12 of 17). The
rate of FTR after any major complication was 13!6 per cent
(17 of 125). The mortality rate after any relaparotomy and
PPH grade B/C was 12 of 71 (17 per cent) and 7 of 44 (16
per cent). Overall mortality after CR POPF was eight of
66 (12 per cent), with separate mortality rates after POPF
grade B and C of one of 41 (2 per cent) and seven of 25 (28
per cent) respectively.
The FTR rate in the high-volume centre was 11 of 57
(19 per cent), compared with six of 68 (9 per cent) in
medium–low-volume units (Fig. 1). In multivariable analy-
sis assessing the same predictors as for postoperative com-
plications (Table 4), medium–low unit volume was not an
independent predictor of higher FTR (OR 0!49, 95 per
cent c.i. 0!26 to 1!63; P = 0!243).
Discussion
These data indicate that results similar to those in
high-volume expert centres may be obtained within a
single-payer PD service practising a moderate degree
of centralization. The sole high-volume centre had out-
comes on a par with those from internationally renowned
© 2020 The Authors. www.bjsopen.com BJS Open




4.2.1 Supplementary results not included in paper II  
 
Vascular resection  
There were significantly more vascular resections performed in the high-volume patient 
population with an OR of 3.1 (CI 1.7-3.5) compared to patients treated at medium-low 
volume units. There were no differences in postoperative outcomes after vascular resection 
between the two volume categories.    
      
 Total                                                                       
n=394 
High-volume unit          
n= 201 
Medium/low volume 
units combined                            
n=193 
Age- and gender adjusted 
comparison high vs 
medium/low volume units1 
Procedures                                                                                                                                                                           OR (95% CI), p-value 
Any vascular resection (patients) 70 (18%) 50 (25%) 20 (10%) OR 3.1 (1.7-5.3) p<0.001 
Postoperative outcomes for patients with concomitant vascular resection (n=70) 
Accordion 3-6 25 (36%) 19 (38%) 6 (30%) OR 1.5 (0.5-4.5) p=0.492 
Relaparotomy 18 (26%) 15 (30%) 3 (15%) OR 2.8 (0.7-11-4) p=0.153 
Post-pancreatectomy haemorrhage 
grade B/C 
19 (27%) 14 (28%) 5 (25%) OR 1.2 (0.4-3.8) p=0.808 
Postoperative pancreatic fistula 
grade B/C 
7 (10%) 4 (8%) 3 (15%) OR 0.5 (0.1-2.4) p=0.352 
90-day mortality 4 (6%) 3 (6%) 1 (5%) OR 1.2 (0.1-12.2) p=0.888 
1 Logistic regression analyses (adjusted for age and gender) of high volume as predictor of procedures and outcomes, with medium/low volume as 
reference 
 





Figure 13: 90-day mortality (Failure-to-rescue) following relaparotomy, POPF grade B/C and PPH grade B/C, 
stratified for unit volume category 
The national failure-to-rescue rates following relaparotomy (any), POPF grade B/C and PPH 
grade B/C were 17%, 11% and 16%, respectively. 15 out of 17 patients who died within 90 
days experienced at least one of these three complications. Conversely, the national 90-day 
mortality rate among patients who did not experience neither of these was 2 out of 269 
(0.7%). 
 
Histopathological distribution of resected specimens  
Specimens n    (%) 
Any malignancy 324 (82) 
PDAC 161 (41) 
CBD cancer 58 (15) 
Duodenal cancer 36 (9) 
Ampulla cancer 30 (8) 
Other malignancies 39 (10) 
Benign disease 69 (18) 
IPMN 25 (6) 
Pancreatitis 11 (3) 
Other 33 (8) 
Table 3: Histopathology distribution in 
pancreatoduodenectomy specimens in Norway 
2015-2016 (n=393). PDAC: Pancreatic ductal 
adenocarcinoma. CBD: Common bile duct. 
IPMN: Intraductal papillary mucinous dysplasia.  
(Note: Table 3 is also displayed under 1.3, 




Outcomes stratified by histopathology 
 PDAC 
(n=161) 






Outcomes n (%) 
Relaparotomy 30(18.6) 30(18.4) 60(18.5) 11(15.9) 
POPF grade B/C 15(9.3) 31(19.0) 46(14.2) 20(29.0) 
PPH grade B/C 19(11.8) 18(11.0) 37(11.4) 7(10.1) 
90 d-Mortality 4(2.5) 11(6.7) 15(4.6) 1(1.4) 
Non-R0 105(66.5) 77(47.2) 182(56.9) - 
 
Table 3: Postoperative outcomes stratified by histopathology. POPF: Postoperative pancreatic fistula, PPH: Post-
pancreatectomy haemorrhage. 
 
The rates of non-R0 in PDAC-specimens with and without concomitant vascular resection 
were 43 out of 52 (83%) and 62 out of 106 (58%), respectively. 
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4.3 Paper III 
 
Progress for the few: Treatment and survival after pancreatic ductal adenocarcinoma in 
a 15-year national cohort 
(Submitted for review, May 2021) 
A total of 10630 patients were diagnosed with PDAC between 2004 and 2018. The fraction of 
patients who did not receive any tumour-directed treatment (resection or chemotherapy) 
decreased over time from 52.9% in 2010 to 37.9% in 2018, p for trend <0.001.  
During the studied period a rising proportion of patients underwent formal tumour resection 
with a peak of 18.9% for 2018, and the median age of those resected increased by four years. 
The largest increase in resection rate was for patients aged 75+, with an OR for resection of 
2.11 (CI 1.59 – 2.79) when diagnosed 2014-2018 compared to 2004-2008. 
 
Figure 14: Trend in resection rate 2004-2018 for a) all ages and b) stratified by age group 
 
A marked rise in provision of perioperative CTx was found, especially for neoadjuvant CTx 
(all ages) with OR (95% CI) of neoadjuvant CTx for 2014-2018 of 4.44 (2.58-7.63) compared 
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to 2010-2013. No change in provision of palliative CTx was observed (p=0.201) for the 
resected. An increase in use of palliative CTx for non-resected patients was demonstrated, 
mostly due to provision to patients aged 75+ with an OR (95% CI) for palliative CTx for 
2014-2018 of 1.72 (1.35-2.20), with 2010-2013 as reference.  
Median overall survival (IQR) for resected patients increased from 16.0 months (8.3 – 33.0) 
for 2004-2008 to 25.1 months (12.4 – 49.2) for 2014-2018, and the 3-year survival (CI) 
improved from 22.0 % (17.9-26.4) to 36.4 % (32.2-40.6). 
 
Figure 15: Survival plots (KM) for a) all patients, b) resected patients and c) non-resected patients with stratifies 




4.3.1 Supplementary results not included in paper III 
 














Resection rate (%) 14.1 14.1 13.8 14.3 13.1 0.807 
2010-2018 (-2017 for palliative chemotherapy) 





















































Figure 16: Regional resection rates and provision of chemotherapy. Patients categorized by residing regional 
health authority (RHA). Missing data for residing RHA for 5% of patients, and these were excluded. 
 
The resection rates were equal between the four regions. Besides provision of palliative CTx 
to non-resected patients (range from 37.1% in RHA North to 50.6% in RHA Central, 
p<0.001) and neoadjuvant CTx (range from 7.2% in RHA West to 17.9% in RHA Central, 








Regional survival (2004-2018) 
 
Figure 17: Kaplan-Meyer plots for overall survival 2004-2018 stratified by residing regional health authority, a) all 
patients with PDAC diagnosis, b) resected patients and c) non-resected patients. 
 
There was no difference in survival between the complete PDAC populations in the four 




5  DISCUSSION 
 
5.1 National short-term outcomes (Paper I and II) 
The contemporary results and practice of pancreatoduodenectomy in Norway are reassuring 
in comparison to other recent population-based reports. (29, 56, 68, 69) The complete, 
unselected 5-year cohort (2012-2016) analysed in paper I demonstrated a national mortality 
rate in line with publications from expert centres. (48) Of note, the follow-up in paper I 
included treatment given in any transfer or re-admitting hospital and deaths occurring outside 
hospitals and extended in time beyond the more commonly evaluated in-hospital data. The 
dataset for paper II allowed for more granular analyses of procedure-specific complications 
for the latter two years of the cohort previously studied in paper I. Sánchez-Velázquez et al 
published in Annals of Surgery in 2019 an international multi-centre study from expert 
centres where outcomes from PD in a cohort of low-risk patients were used to benchmark cut-
offs for acceptable levels of postoperative outcomes, including procedure-specific 
complications. (48) By comparison, we showed in paper II that both the single high-volume 
unit and the four medium-low volume units in Norway combined (i.e., the complete national 
cohort) scored within their benchmarked cut-offs for operation duration, blood transfusion, 
length-of-stay, POPF, PPH and mortality. The specific FTR rate for the high-volume centre 
was higher in terms of observed absolute figures (20%), but the national FTR-rate (11%) was 
on par with the benchmark value (9%). This was in spite of the fact that the abovementioned 
benchmarked levels were based on data from a low-risk cohort defined by strict criteria that 
excluded almost one in two patients, while our data included every single patient treated 
across the nation during the given time span: lock, stock and barrel. In addition, the 
benchmark values (48) also included complications scored as Clavien-Dindo grade 3a in the 
denominator of the FTR-rate, while our studies only included complications corresponding to 
Clavien-Dindo grade 3b or higher. The absence of patient selection, the extended follow-up 
time in paper I, and the completeness in follow-up in both papers further support the finding 
of an acceptable level of short-term complications following pancreatoduodenectomy in 
Norway today.  
Analyses of postoperative mortality after pancreatic surgery have also been reported from 
other principally coeval population-based and unselected national cohorts. The national 90-
day mortality rates after PD was in France 9.2% (68) and in Germany 9.1% after any major 
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pancreatic resection. (56) Both countries have a combination of public and private health care 
services and despite overt intentions (49, 54, 56, 68) have not yet carried out the centralization 
process in practice. Both Sweden and the Netherlands practice organizational models similar 
to the Norwegian one and report results more comparable to our findings, with a 3.5% 90-day 
mortality rate after PD for periampullary malignancies or pancreatic cancer (14) and 4% in-
hospital mortality after PD on any indication (26), respectively. 
Besides the established centralization of surgery, the explanation behind the low mortality 
rates and overall beneficial contemporary short-term outcomes after pancreatic surgery in 
Norway, as demonstrated in paper I and II, is not obvious. Intuitively, a conservatism in 
selection of candidates for surgery might be suspected, but there are few signs of this. By 
narrowing the “clinical operability” frame to exclude patients with characteristics or 
comorbidity signifying a perioperative high-risk profile, it is possible to select towards 
beneficial short-term outcomes after surgery. The inherent consequence will be lower 
procedure incidence rates per population. The incidence of PD per population (any indication) 
in Norway was 3.6 procedures per 100 000 inhabitants for 2012-2016 in comparison to the 
abovementioned French cohort with 3.3 procedures per 100 000 inhabitants between 2007 
and 2012. The age among patients resected with PD in Norway is higher or in line with other 
western countries. (14, 56, 68) In paper I, more than one fifth of patients were aged 75+ at the 
time of the PD and were found to have an increased risk for mortality within 90 days 
compared to patients aged <65 years (OR 13.8 (95% CI 4.2-63.0). The extent of the surgical 
procedure may also influence on the achieved short-term outcomes. In line with the literature 
(12, 13) our data confirmed that concomitant multi-visceral resection (MVR) was an 
independent predictor of both relaparotomy and mortality. There are few population-based 
reports on the incidence of concomitant MVR that can serve as adequate comparisons to the 
cohort from paper I and an associated analysis of DPs in Norway (16) (5% MVR-rate for PDs 
and 2.9% for DPs). A publication from the US NSQIP database, using a broader definition 
than ours, reported a rate of 3% of concomitant MVR in PDs. (12) The majority of literature 
suggests that vascular resection (arterial or venous) during pancreatic resection increases both 
morbidity and mortality. (9, 42, 70) Others (10) have demonstrated no increased complication 
burden after venous resection in PD, which is in line with our findings where vascular 
resection during PD was not a predictor of neither relaparotomy nor mortality in paper I and 
found only to be a predictor of PPH grade B/C in paper II. Nevertheless, the rate of vascular 
resection during PD in Norway was 15% from 2012-2016, and 33.5% in PD for PDAC in 
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2015-2016, which is on par with or higher than comparable cohorts (70, 71) and even series 
from expert centres. (72) Although previously validated (73), the method used for computing 
the Charlson comorbidity index (CCI) in paper I relies on the quality of coded diagnoses 
within the NPR, which we believe to be of questionable accuracy. Hence it cannot serve as a 
reasonable means of external comparison of the comorbidity burden to other cohorts. In sum, 
considering the population-based incidence of pancreatic resections, the relatively high age 
among the resected Norwegian patients and little evidence of less extensive surgery, our 
results do not point to a conservative resection practice as an explanatory factor to the 
obtained beneficial outcomes and the low short-term mortality in particular. 
 
5.2 National trends in treatment and survival from pancreatic ductal adenocarcinoma 
(paper III)  
The literature on treatment of PDAC from the past decades suggest that survival is improving. 
Novel strategies for expanding the resectability criteria have been taken up into routine 
practice including techniques for vascular resection and downstaging of locally advanced 
disease by preoperative CTx. The introduction of FOLFIRINOX in both palliative and 
adjuvant settings have demonstrated marked survival benefits in comparison to traditional 
regimens. Of note, these claims of progress are based on highly selected cohorts of patients 
who either fit the strict inclusion criteria for surgical or drug trials, or who have access to 
treatment at expert surgical centres. Even in western countries the vast majority of patients 
with PDAC do not fit into either category due to either high age or other frailty, advanced 
tumour stage at time of diagnosis or organizational or economic concerns.  
Whether the abovementioned progress is visible when assessing population-based cohorts, 
including every single patient and health care provider, is less explored. In paper III we 
analysed trends in treatment practice and long-term survival in a national 15-year cohort of all 
patients diagnoses with PDAC. The studied time frame covered the centralization of decision 
on resectability and provision of surgery to oncological HPB units, and establishment of a 
national onco-surgical clinical society and official practice guidelines. We found that the 
proportion of patients diagnosed with PDAC who did not receive tumour-directed therapy did 
decrease over time. Yet, by 2018 still four in ten Norwegian patients diagnosed with PDAC 
did not reach neither surgery nor CTx. To no surprise, their survival was practically 
unaffected over time with a sparse net rise in median survival of about one week from 2010-
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2013 to 2014-2018. As stated by many others, biology is still king of this disease and novel 
preventive strategies, or tools of treatment are sorely needed to obtain a substantial increase in 
long-term survival from PDAC. Although technical surgical progress as mini-invasive PD 
and complex vascular resections should be applauded, it is probably not herein the solution to 
the steadily grim survival prospects from PDAC lies.  
From early to late study period the odds of reaching resection increased by 54% and peaked 
with a resection rate (all ages and stages) for 2018 of 18.9%. An increasing proportion of 
resected patients were provided with perioperative CTx, and in particular neoadjuvant CTx 
(four-fold increase in late vs early part of the study period that included data on CTx). 
Simultaneously, in spite of more and older patients being resected and a steep rise in 
neoadjuvant CTx signifying at least borderline resectability, the median survival after 
resection increased by 9 months up to a median OS of 25.1 months (IQR 12.4 – 49.2) and a 3-
year OS of 36.4 % (IQR 32.2-40.6) for 2014-2018. The reasonable morbidity burden and 
steadily low mortality following pancreatic resections in Norway have probably over time 
allowed skewing the “clinical operability” frame to a situation that nowadays include older 
and more frail patients with early-stage disease, and thereby contributed to increased resection 
rates. The increased provision of neoadjuvant CTx, which is advocated and practiced only for 
borderline or selected patients with locally advanced tumours or in experimental protocols, is 
contraindicative of a general stage drift towards more early-stage disease and cannot serve as 
a reasonable explanation to the observed increased survival among resected patients. 
However, we know that the quality of radiology is improving, and that high-resolution and 
contrast-enhanced CT, MRI and ultrasound aids in detecting occult metastatic disease 
especially in the liver (74, 75) and also can provide an enhanced evaluation of tumour 
resectability. The introduction of mandatory HPB-unit decision on resectability also includes 
centralization of the radiological assessments. One might hypothesize that this has led to a 
superior selection of surgical candidates, with more actual non-metastatic (within the limits of 
radiological assessment) patients being resected, and that this contributes positively to the 
survival in the resected cohort. I.e., while the surgical and oncological progress seemingly 
have led to more (and older) patients reaching resection, the radiological improvement may 
have aided in selecting the right patients for surgery. The increased use of perioperative CTx 
regimens might also influence positively to the increased survival post resection. 
For the non-resected the rate of provision of palliative CTx increased, especially among the 
elderly, whereas their survival remained largely unchanged over time. As FOLFIRINOX was 
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not used in a broad scale in Norway before 2018, the potential survival gain from this regimen 
is not assessable within this study cohort. Importantly, the observed, though modest, increase 
over time in proportion of patients who reach resection have likely left the cohort of non-
resected with a converse drift towards a heavier disease burden and/or comorbidity. Although 
we documented that a larger proportion of these embark on palliative CTx regimens, the 
potential benefit in survival from the available CTx regimens might be camouflaged by an 
increased cancer load and other frailty in the cohort left without resection. The data on CTx 
from NPR did not allow analysing the completeness of the planned cycles.  
A similar and principally coeval nationwide evaluation from the Netherlands showed parallel 
trends to our results (21), with increased resection rates, use of CTx and 3-year survival. In 
comparison, with reservation regarding analytical dissimilarities between the two datasets, the 
Norwegian PDAC cohort apparently received more treatment (in particular palliative CTx for 
the non-resected), and at the end of the study periods the median and 3-year OS after 
resection were higher in Norway (18.1 months (IQR 17.1-19.1) vs 25.1 months (IQR 12.4 – 
49.2) and 25.4% (IQR 23.3 – 27.8) vs 36.4% (IQR 32.2 - 40.6), respectively). Another 
nationwide cohort from Sweden, a country practicing an organizational model very similar to 
the Norwegian one, reported resection rates and a 3-year OS for PDAC almost identical to our 
results, but a lower 5-year OS (6% vs 17.5%). (14) The same reservation regarding analytical 
dissimilarities applies to this comparison. Noteworthy, the population-based median survivals 
post resection reported from Sweden (14) and Norway (present paper III, submitted) are in 
line with what was obtained in the ESPAC trial (76) (all included patients assigned to 
adjuvant CTx and with a low protocol violation rate), but inferior to single institution series 
from expert centres. (77)  
Will a PDAC population as a whole benefit from higher resection rates or increased survival 
when treated in a PD service practicing a high rate of concomitant vascular resection? We 
showed in paper I and II that the uptake population of the sole high-volume centre more often 
had a simultaneous vascular resection during their PD procedure, with only a negligible cross-
regional patient drift that was adjusted for in the analyses. In paper III we could not find 
evidence of neither corresponding higher resection rates nor superior survival after resection 
in the regional population treated at the high-volume unit. Importantly, regarding the regional 
survival, the analyses were only performed on the complete study cohort from 2004-2018 as a 
whole, and vascular resection techniques did not gain territory in everyday practice until the 
latter half of this period. Herein lies a possibility of overlooking an effect that would have 
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been identifiable in subgroup analyses of more granular time periods. Concerning the 
threshold for simultaneous vascular resection for pancreatic malignancies, no comprehensive 
criteria are included in the national guidelines. While the present studies (paper I and II) 
suggest that vascular resection can be practised without an excessive overall complication 
burden, most evidence support the contrary (42, 78). In light of the exceedingly high R1-rate 
in PDAC specimens in general and for specimens from PDs with vascular resection in 
particular (currently in Norway four in five are R1, see supplementary results paper II and 
other publications (79, 80)), a certain sobriety should probably be maintained towards the 
long-term survival benefit from this additional procedure, beyond allowing resection at all, as 
an R0-resection is rarely achieved anyway. (79)  
 
5.3 On regional disparities and the level of centralization (Paper I-III) 
It is a declared goal from the national health care governments that access to, and quality of 
the health care provided should be equal for all citizens and non-dependent of one’s region of 
residency. There exists no valid argument to defend large discrepancies in population-based 
procedure incidence of pancreatic resection, resection rates for PDAC or key surgical 
outcome metrics between the four administrative regional health regions (RHAs) in Norway. 
Reassuringly, we found little evidence of such. In spite of a large span in regional population 
density and size, as well as unit surgical case volume, the present studies do not point out any 
major discrepancies in the amount or quality of provided health care services in terms of 
pancreatic resection or PDAC treatment across the nation.  
In paper I we demonstrated practically identical regional procedure incidences of PD between 
the four regional populations and equal 90-day mortality rates, pointing to a uniformity in 
practice of evaluation of resectability and selection for surgery. A difference in rate of 
relaparotomy was however identified. Interestingly, the region reporting the highest 
relaparotomy rate experienced no deaths within 90 days after PD, and contrariwise the region 
with the lowest relaparotomy rate saw the highest 90-day mortality rate. This might be a 
coincidence and a result of small absolute figures but spurs a speculation of different 
approaches to non-major anastomotic leaks. Although a relaparotomy is never a desired event 
it may be necessary, and a timely reintervention for intraabdominal complications is key to 
maintain low FTR-rates. Both paper I and II confirmed that patients treated in one of the 
regions (RHA South-East, surgical unit OUS Rikshospitalet) were more likely to have a 
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concomitant vascular resection with their PD. This held true after adjusting for interregional 
patient drift and is hence likely a consequence not of patient case mix but of diverging 
attitudes between the surgical milieus towards the theoretical survival benefits from this 
adjunctive procedure (beyond allowing for pancreatic resection at all). Of equal importance, 
with limitations due to small absolute figures and limited data on extent of the reconstruction, 
having a concomitant vascular resection at a medium/low volume unit was not associated 
with an increased risk of postoperative adverse events in comparison to the high-volume unit. 
For PDAC, no regional differences were found in key outcomes such as resection rates and 
survival. However, there was some variation in provision of both palliative CTx for the 
unresected as well as neoadjuvant CTx for patients who later underwent tumour resection. 
These discrepancies are probably not attributed to patient factors, but rather reflect intended 
diverging practice patterns between the regions and this deserves further attention. On the 
other hand, the observed variations in use of neoadjuvant CTx were not reflected in regional 
survival rates after resection. Also, in light of the modest survival gain and impact on quality 
of life, embarking on palliative CTx for PDAC should not be considered an unnuanced 
quality metric. It is somewhat a question of “temperament” or perspective of life in both 
patients and health care providers, and despite national guidelines it remains susceptible to 
individual judgement.  
To recapitulate, the amount and quality of pancreatic resections and PDAC treatment is alike 
across all regions in Norway, and the unselected national short-term outcomes from surgery 
and PDAC survival is beneficial in comparison to other national cohorts and established 
benchmarks, and in some respects even in line with expert center series. So, has the current 
organizational model struck the balance between geographical/organizational concerns and 
postoperative outcomes for pancreatic resections, or would the national outcomes improve 
further by practicing an even higher degree of centralization? In light of the strict adherence 
within the surgical society and the current beneficial nationwide results obtained, the 





Figure 19: Accordion grade 3 or higher, 90-day mortality and failure-to-rescue after pancreatoduodenectomy 
2015-2016, stratified for high-volume vs medium/low volume units (from paper II).  
 
In paper II we used 40 PDs a year as a cut-off for high volume and showed that the four 
medium-low volume units combined overall did not score inferior to the single high-volume 
unit in terms of key short-term outcomes from PD. (Figure 12). The rate of POPF was indeed 
lower in the high-volume unit and their index length-of-stay (before transfer) was shorter, but 
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High-volume centre (n= 201)
Medium–low-volume units combined (n= 193)
Medium-volume unit
Low-volume unit
a Postoperative complications (Accordion grade 3–6); b 90-day mortality; c failure-to-rescue. Multivariable analysis with high volume as reference (odds
ratio (OR) 1!00): a OR 1!28 (95 per cent c.i. 0!82 to 1!98), P = 0!274; b OR 0!24 (0!07 to 0!82), P = 0!023; c OR 0!49 (0!26 to 1!63), P = 0!243.
and for PDs without concomitant vascular resection, a
lower rate of classical PD (versus pylorus-preserving PD)
and a higher rate of any vascular resection. Most arterial
resections were performed in the high-volume centre (14
of 16); none of these 16 patients died within 90 days.
Postoperative complications
Crude rates of postoperative complications and univariable
comparison between volume categories are presented in
Table 3. Major complications occurred in 125 patients (31!7
per cent). Results from multivariable analyses are presented
in Table 4. When analysing centre volu e category as a
predictor of postoperative outcomes, medium–low volume
was a predictor of lower mortality within 90 days (OR 0!24,
95 per cent c.i. 0!07 to 0!82) but of a higher rate of CR
POPF (OR 2!52, 1!43 to 4!43). Medium–low-volume unit
did not independently predict occurrence of any major
complication, relaparotomy or PPH grade B/C. Impor-
tantly, variation in the use of vascular resection between
the volume categories was adjusted for.
Failure-to-rescue
Detailed patient data for all patients who died within
90 days are shown in Table 5. All but four of the patients
who died within 90 days experienced at least one major
surgical complication within 30 days: CR POPF (8 of 17),
PPH grade B/C (6 of 17) and relaparotomy (12 of 17). The
rate of FTR after any major complication was 13!6 per cent
(17 of 125). The mortality rate after any relaparotomy and
PPH grade B/C was 12 of 71 (17 per cent) and 7 of 44 (16
per cent). Overall mortality after CR POPF was eight of
66 (12 per cent), with separate mortality rates after POPF
grade B and C of one of 41 (2 per cent) and seven of 25 (28
per cent) respectively.
The FTR rate in the high-volume centre was 11 of 57
(19 per cent), compared with six of 68 (9 per cent) in
medium–low-volume units (Fig. 1). In multivariable analy-
sis assessing the same predictors as for postoperative com-
plications (Table 4), medium–low unit volume was not an
independent predictor of higher FTR (OR 0!49, 95 per
cent c.i. 0!26 to 1!63; P = 0!243).
Discussion
These data indicate that results similar to those in
high-volume expert centres may be obtained within a
single-payer PD service practising a moderate degree
of centralization. The sole high-volume centre had out-
comes on a par with those from internationally renowned
© 2020 The Authors. www.bjsopen.com BJS Open
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Figure 18: Concurrent development during the study period for HPB service organization and core 
treatment metrics and outcomes for resectable pancreatic adenocarcinoma (from paper III) 
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their 90-day mortality and FTR-rate was higher (mark, the latter not statistically significant). 
Subacute complications to pancreatic surgery may well be discovered after primary discharge 
from the operating unit and considering vast geographical distances the proximity to and post-
discharge auspice from the operating facility may be of importance to secure timely treatment 
or surgical reintervention. Of note, various definitions of a high-volume pancreatic surgical 
unit exist, and according to the more commonly applied one (>20 PDs a year) 95.9% of 
patients in this two-year cohort (paper II) were treated in a high-volume facility. 
Moreover, sound arguments against an unlimited centralization do exist. Among reasonings 
towards a practice of moderate centralization are administrative organizational issues and 
patient concerns beyond short-term surgical outcomes. (81) These especially hold true for 
sparsely inhabited and vast geographical areas. (82) Also, in contradiction to the perceived 
linear relationship between unit volume and short-term outcomes, some studies have failed to 
prove additional gain between medium and high-volume units (29, 46, 83), which suggest that 
a ceiling effect in terms of unit volume may be reached. Surgeon experience with other 
anatomical related surgery is also proposed to compensate for a lower volume of pancreatic 
resections (84), and all the five Norwegian HPB units have an annual volume of other major 
HPB and upper GI resections of more than four-fold their PD volume.  
With some reservation regarding the sole low-volume unit, our data do not suggest that a 
further centralization of pancreatic surgery in Norway will benefit the outcomes to a degree 
that would outscore the negative side effects on organizational and administrative concerns.  
 
5.4 Follow-up beyond index stay and the value of complete population-based cohorts 
including “warts and all” 
In paper I we showed that after PD one in five relaparotomies occurred outside the index unit, 
and that two in five deaths within 90 days occurred in a transfer hospital, in a primary health 
care facility or at home. An increase of 25% in relaparotomy rate and almost 70% in mortality 
rate from that of the operating (index) unit is substantial. As previously shown by others (85), 
the 90-day mortality was double that of the 30-day mortality rate. From another publication 
by our group we learned that by including transfer and readmission stays the length-of-stay 
after PD in Norway increased by more than 50% as opposed to the commonly reported index 
unit length-of-stay. (30) Caution must be taken when comparing diverging results for e.g., 
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mortality or complications as long as the entities themselves are not alike or well-defined, and 
the completeness and quality of follow-up data diverge or are not reported on.  
Scientific publications even in high impact journals, especially single institution resection 
series, sometimes scarcely touch upon or even lack any description of the data quality of 
follow-up after surgery. Many include only in-hospital data for both morbidity and mortality 
(86), which we know from paper I, and as discussed above, can lead to an underestimation of 
the real-life complication burden. A single-unit resectional cohort of major pancreatic 
resections from Heidelberg, Germany assessed institutional data only and reported a)n in-
hospital mortality rate of 3.8%. (86) In comparison, a complete, nationwide audit of all major 
pancreatic resections in Germany using national administrative data only, published an in-
hospital mortality ranging from 6 to 13% between high and low volume units. (56) The 
dissimilarity this exemplifies can in theory reflect different completeness, quality and 
methods for data gathering, as discussed in the previous section, but also the difference 
between results obtained in a selected patients series treated in a high-volume expert centre 
contra a whole nation, including all patients, surgeons and hospitals; warts and all. As long as 
the data quality and completeness in follow-up are not alike or not even accounted for, we 
cannot decide. These two seemingly alike outcome variables (“in-hospital mortality”) should 
be compared with much caution, or not compared at all. Both hold scientific value but most 
likely reflect different clinical situations and populations, and the foundation of the data sets 
are not akin.  
Case series publications on the surgical feasibility of, and the survival obtained in patients 
undergoing extensive radical surgery for PDAC (i.e., arterial resection) often overlook the 
selection bias inherent to such selected patient series. Not only do these patients have access 
to surgery at expert centres, but from being found fit enough for any treatment (chemotherapy 
with high toxicity and extensive surgery) and having a tumour biology responsive to CTx, 
they are biological winners to begin with. By performing intention-to-treat analyses where all 
patients with advanced tumour stage considered for, or at least those started with, 
downstaging/neoadjuvant CTx are included in the denominator, it will be possible to display a 
more correct image of the survival benefits from these extensive and high-morbidity surgical 
procedures. (87) Randomized controlled trials on long-term survival after CTx alone vs CTx 
with surgical resection for locally advanced pancreatic cancer are lacking.  
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5.5 Methodological considerations 
Observational studies of large cohorts like the three studies included in this thesis, and in 
particular when using administrative data, hold some inherent weaknesses and strengths. 
First, the variables that are available are often crude and other core variables that may 
influence on the studied outcome may be lacking. This stands in contrast to intervention 
studies allowing for real-time gathering of predefined and pinpointed granular clinical 
information. Another weakness is the necessity of making assumptions when defining 
variables without any reasonable cost-effective means of validation. For example, the 
definitions of relaparotomy and readmission used in paper I cannot exclude rare intercurrent 
and unrelated conditions, but we assumed that the vast majority of events were related to the 
index surgery. Likewise, the incidence of vascular reconstruction in paper I and provision and 
setting of provided chemotherapy in paper III relies on the accuracy of procedure coding, 
which we assumed was high. Core variables for both paper I and paper III were crosschecked 
against EPJ for minor subsets of patients and the algorithms were found to be of good quality. 
The uncertainty linked to the assumptions behind the definitions are also less important when 
comparing data across regions, or over time.  
Among the obvious strengths of large-scale studies of unselected patient cohorts is the ability 
to provide a picture of the real-life practice. However, while cohort studies may benchmark 
outcome metrics and describe the effect measures of the assessed predictors, they cannot 
provide evidence of more than significant associations and only suggest or hypothesize causal 
effects. In contrast to randomized controlled trials, observational studies comparing patient 
groups are prone to unrecognized baseline biases that are not accounted for in the analyses or 
interpretations. This may be minimized by the sole use of inclusion and outcome metrics that 
are unequivocally defined, such as pancreatic resection and death. 
In paper II, we did statistical comparisons of several rare events (specific postoperative 
complications, mortality and failure-to-rescue) in two like-sized but somewhat small cohorts. 
Herein lies the possibility of making a type II error by rejecting a true finding that simply did 
not reach statistical significance due to small sample sizes. In retrospect it is obvious that an 




6 CONCLUSIONS AND CLINICAL IMPLICATIONS 
 
• The contemporary national short-term outcomes from pancreatoduodenectomy in 
Norway are beneficial in comparison to other national cohorts and in line with 
established clinical benchmarks for a standard patient population.  
 
• Overall, the short-term outcomes after pancreatoduodenectomy obtained in the four 
medium-low volume hospitals were not inferior to the high-volume unit. We found no 
difference in survival for pancreatic ductal adenocarcinoma between the regional 
populations. The degree of centralization as practiced today seems balanced. 
 
• A rising proportion of patients with pancreatic ductal adenocarcinoma reach resection 
and the median and 3-year survival is increasing. 
 
• Although decreasing over time, the proportion of patients diagnosed with pancreatic 
ductal adenocarcinoma who do not reach any tumour-directed therapy is still close to 




7 FUTURE FOCUS OF RESEARCH AND 
PERSPECTIVES 
 
Among the noteworthy findings during the work in this thesis was the high proportion (close 
to four in ten) of PDAC patients who by present time, and in a health care system with few 
economical limitations, still do not reach any form of tumour-directed treatment. Even though 
they numerically outscore the resected cohort by a two-fold, they receive a bare minimum of 
resources from the surgical and oncological clinicians and are left in the care of community 
health care resources and occasionally an ambulant palliative care team. Another aspect 
worthy of attention is the increasing proportion of non-resected PDAC patients aged 75 or 
older who commence on palliative CTx (currently in Norway about 30%). In light of the 
limited prospects of survival gain from this treatment, its innate implications on quality of life 
especially for the elderly and frail and including often long travel distances to treatment 
facilities, it is entirely possible that we provide “too much” treatment to this group. Further 
studies focusing on the balance between quality-of-life against the limited survival gain from 
such treatment would be useful. In 2020 a dedicated quality registry for patients with 
pancreatic ductal adenocarcinoma was funded as a sub-registry of the Cancer Registry of 
Norway and will hopefully provide data that will allow for further future investigations into 
these matters.  
The modern long-term survival prospects from PDAC are uniquely poor in comparison to 
most other cancers. Refining the presently available treatment options, exemplified by more 
extensive surgery, debates on the optimal graft material for vascular reconstructions, 
centralization of surgery to high-volume units and novel but toxic chemotherapy (as 
FOLFIRINOX) will highly likely not turn the table. A large proportion of PDAC patients are 
nevertheless not in the position to receive either. Research resources should probably instead 
be directed towards the emerging initiatives exploring novel biomarkers to identify 
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Abstract
Background: Centralization of pancreatic resections is advocated due to a volume-outcome associ-
ation. Pancreatic surgery is in Norway currently performed only in five teaching hospitals. The aim was to
describe the short-term outcomes after pancreatoduodenectomy (PD) within the current organizational
model and to assess for regional disparities.
Methods: All patients who underwent PD in Norway between 2012 and 2016 were identified. Mortality
(90 days) and relaparotomy (30 days) were assessed for predictors including demographic data and
multi-visceral or vascular resection. Aggregated length-of-stay and national and regional incidences of
the procedure were also analysed.
Results: A total of 930 patients underwent PD during the study period. In-hospital mortality occurred in
20 patients (2%) and 34 patients (4%) died within 90 days. Male gender, age, multi-visceral resection and
relaparotomy were independent predictors of 90-day mortality. Some 131 patients (14%) had a rela-
parotomy, with male gender and multi-visceral resection as independent predictors. There was no dif-
ference between regions in procedure incidence or 90-day mortality. There was a disparity within the
regions in the use of vascular resection (p = 0.021).
Conclusion: The short-term outcomes after PD in Norway are acceptable and the 90-day mortality rate
is low. The outcomes may reflect centralization of pancreatic surgery.
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Introduction
PD is considered a complex surgical procedure and associated
with significant postoperative morbidity and mortality, even in
modern series.1–3 The long-term survival from surgery is very
limited for adenocarcinoma,4 and uncertain for cystic neo-
plasms,5 and quality-of-life following PD can be substantially
impaired.6,7 Therefore, it is important that short term outcomes
are monitored and optimized if such surgery is to be justified.
Single-centre series from expert centres have consistently re-
ported improved outcomes and low mortality figures for PD.8,9
Notably, high-volume, tertiary centres may not reflect the
average centre or surgeon performance, and nationwide audits
have shown inferior outcomes compared to expert centre re-
ports.1,3 Only complete, unselected cohorts including all patients
and all surgeons, with follow-up extending beyond in-hospital
data can provide a correct picture of the real-life outcomes.
Several analyses of volume–outcome relationships indicate
inferior outcomes after PD performed in low-volume centres,
and different cut-off values for the minimum annual case load
have been proposed.1,3,10–12 Internationally there is currently a
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large variation in organizational models and degree of centrali-
zation of pancreatic surgery.1,3,10,13 Recent nation-wide reports
from both France and Germany propose that superior short-
term outcomes may be achieved with further centralization of
major pancreatic resections.1,3 However, most papers exclusively
report outcomes from health systems with non-centralized
pancreatic surgery, and studies of outcomes achieved after
centralization are lacking. Pancreatic surgery in Norway is strictly
centralized to a limited number of university hospitals. Neither
the incidence, nor the short-term outcomes of PD in Norway
have previously been evaluated and the impact of vascular and
multivisceral resection remain unknown.
The aim of this study was to describe the short-term outcomes
after PD in a complete, contemporary national cohort within the
current organizational model, and secondly to assess for relevant
regional disparities in practice or outcomes.
Methods
Ethics
Centre for Clinical Documentation and Analysis (SKDE) in
Tromsø holds a licence from the national Data Protection Au-
thority allowing access to and analysis of NPR-data, and addi-
tional research committee application to evaluate these data was
waved according to Norwegian law.
Study design
This study was an observational cohort study of all patients who
underwent PD in Norway during the five-year period of January
2012 to December 2016. Resections for both malignant and
benign disease were included. The study was conducted and
reported in accordance with the STROBE guidelines for obser-
vational studies.14
Health care in Norway
Norway has a universal, public health care system covering some
5.3 million inhabitants. The nation is organized into four inde-
pendent regional health authorities (RHAs). All hepato-
pancreato-biliary (HPB) surgery is performed within five
public university hospitals; one HPB unit in each of the four
RHAs, with the exception of RHAWest which has two collabo-
rating units. All five pancreatic centres have access to advanced
intervention radiology, expertise on vascular surgery and multi-
disciplinary intensive care wards. There is no official national
referral unit for complex pancreatic resections. However, as Oslo
University Hospital Rikshospitalet carries the national trans-
plantation unit, selected patients with complex surgical chal-
lenges may be referred there for a second opinion. HPB-surgeons
from all five units are represented in the HPB-section of the
Norwegian Gastrointestinal Cancer Group, and involved in the
continuous development of national guidelines,15 and study
protocols (e.g. the NorPACT study).16 The national guidelines,15
describe a mandatory preoperative work-up and include
definitions of resectability and of locally advanced disease.
Neither operative technique nor perioperative care is strictly
standardized.
Data gathering
All hospitals in Norway report data to the National Patient Reg-
istry (NPR) for reimbursement, including details on diagnoses,
procedures and hospital stays. Data are identifiable on patient-
level by a unique personal identification number that enables
tracking of treatment episodes across time and centres. The NPR
was searched for NCSP-codes (NOMESCO Classification of
Surgical Procedures),17 denoting PD (JLC 30 or JLC 31) and the
following unique patients journeys were tracked. Both the pa-
tients residing RHA and treating RHAwere registered to allow for
recording of interregional patient drift and referral practices.
Charlson comorbidity index (CCI) was computed using a pre-
viously validated search algorithm for ICD-10 codes in NPR.18–20
Data from NPR are not sufficiently detailed to address compli-
cations specific to the procedure, and hence rates of postoperative
fistula or haemorrhage were not possible to identify.
Definitions
Mortality was assessed at 90 days as a primary outcome indicator,
but all deaths following index surgery were recorded up to 180
days. Relaparotomy was defined by a search for a fixed set of
NCSP procedure codes denoting any laparotomy registered
within 30 days from index surgery during index or any subse-
quent stay, performed in any Norwegian hospital.21 Length-of-
Stay was evaluated as aggregated length-of-Stay (a-LoS),
defined as cumulative number of days after index procedure
spent in any hospital within 30 days, including transfers and
readmissions to own or other institutions. Readmission was
defined as any additional stay in any hospital (direct transfers not
included) within 30 days after index procedure. Details
concerning the search algorithms and definitions used for the
above-mentioned outcomes are described previously.21 Vascular
resection during index procedure was defined by the presence of
NCSP codes denoting any major arterial or venous resection.
Codes denoting only vascular suture, ligature or simple angio-
plasty were not classified as vascular resection.22 Multi-visceral
resection was defined by the presence of NCSP codes denoting
simultaneous formal resection of either stomach (extending
beyond resection of distal stomach as performed with non-
pylorus preserving PD), small bowel or colon during index
procedure. Wedge resections of either of these organs were not
included. Use of procedure codes from the National Patient
Registry has previously been validated, and are considered as
complete and robust data.23 The incidence of the procedure was
defined as number of patients in whom PD was performed per
100 000 registered inhabitants, nationally and in the four
respective geographical regions (regardless of where the resection
was performed) after adjusting for age- and gender composition
in the regional populations.
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Statistical analysis
Crude outcome measures are reported in rates (per cent), means
with standard deviation (SD) or medians with interquartile range
(IQR). Annual procedure-volume per region is reported in
means. Univariate analysis was done using chi-square or Fischer
exact test. The impact of age, gender, Charlson comorbidity
index, vascular resection, multi-visceral resection and RHA
where treated were analysed for mortality and relaparotomy
using models for binary logistic multivariable regression analysis
(step-wise, backwards selection model). For mortality the impact
from relaparotomy was also included. The results are presented
as odds ratios (OR) with 95 per cent confidence intervals (CI)
and p-values. Regional incidences of the procedure were adjusted
for age and gender composition by direct method, and reported
as number of resections per 100 000 inhabitants per year.
Regional use of multi-visceral resection and vascular resection
and incidence of PD were compared by Chi-square-test and
significant results were adjusted for multiple testing (Bonferroni
method). Regional results in a-LoS were compared using
Kruskal–Wallis test. All p-values were two-tailed and a p < 0.050
considered statistical significant. The software used for all sta-
tistical analysis was SAS 9.4 (SAS Institute, Cary NC).
Results
A total of 930 patients underwent PD during the study period.
Follow-up on patient-level was 100% complete. There was a
gradual increase in number of procedures performed per year
from 144 procedures in 2012 to 187 procedures in 2016
(p = 0.006), with a peak of 227 procedures in 2015.
Demographics
There were 497 (53%) male patients. The median age was 68
years (IQR 60–73) with 357 patients (38%) aged <65 years, 379
patients (41%) aged between 65 and 74 years and 194 patients
(21%) were 75 years or older. Some 689 patients (74%) had a
primary pancreatic malignancy. The Charlson comorbidity
index was <2 for 238 patients (26%), 2 for 453 patients (49%)
and 239 (26%) had an index score of >2. A vascular resection or
multi-visceral resection was performed simultaneously to the PD
in 139 (15%) and 44 (5%) patients, respectively.
Mortality
The 90-day mortality rate was 34 out of 930 (4%). Mortality rates
up to 180 days from surgery are presented in Fig. 1. Stratified 90-
day mortality rates are presented in Table 1 and Fig. 2. The over-
all mortality rate was significantly higher among men, and the
largest gender difference was observed for patients aged 75 or
older (p = 0.019). Vascular resection did not result in a raised
mortality rate, whereas multi-visceral resection did. Patients who
experienced a relaparotomy had a more than five-fold higher
mortality rate. Male gender, higher age, and relaparotomy
remained independent significant predictors of 90-day mortality
after multivariable analysis (Table 1).
Relaparotomy
The number of patients who had a relaparotomy within 30 days
from index surgery performed in any hospital and for any
indication, was 131 (14%). Median number of days from index
surgery to (first) relaparotomy was 4 (IQR 1–9). Stratified
relaparotomy rates and results from multivariable analysis are
Figure 1 Over-all postoperative mortality for 2012–2016 (n = 930). Rates at 30, 90 and 180 days after surgery are marked with black boxes and
in-hospital mortality is marked in dotted grey horizontal line. The 90-day mortality rate is substantially higher than the in-hospital mortality
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presented in Table 2. Males experienced a relaparotomy more
often than women, and the largest gender contrast was observed
between patients aged 75 years or older, where 19 out of 94 men
(20%) had a relaparotomy compared to 7 out of 100 women
(7%), p = 0.007.
For 24 out of 131 (18%) patients who had a relaparotomy, this
was performed outside the index hospital. The 90-day mortality
among these was 2 out of 24 as opposed to 14 out of 107 (13%)
among those who had their relaparotomy at the index unit,
p = 0.521. When relaparotomies performed outside the index
hospital were included, the overall relaparotomy rate increased
from 12% (in-hospital) to 14%.
Aggregated length-of-stay and readmissions
Including all transfer- and readmission stays within 30 days
raised the conventional LoS from median 9 days (IQR 7–15) to
an a-LoS of median 14 days (IQR 10–21). The median a-LoS
was 13 days (IQR 10–20), 15 days (IQR 11–21) and 14.5 days
(IQR 11–22) for patients aged <65, 65–74 and 75 years
respectively, with no significant difference between the age
groups, p = 0.122. There was no gender difference with median
a-LoS for women of 14 days (IQR 10–19) compared to 14.5 days
(IQR 10–22) for men, p = 0.112. A-LoS for patients who un-
derwent a relaparotomy was 29 days (IQR 21–30) compared to
13 days (IQR 10–18), p < 0.001. The median a-LoS differed
significantly between the RHAs with 13 days (IQR 9–19) in
RHA South-East, 17 days (IQR 12–23) in RHA West, 16 days
(IQR 12–22) in RHA Central and 15 days (IQR 10–21) in RHA
North, p < 0.001. The proportion of patients who were still
admitted 30 days after index surgery was 65 out of 131 (50%)
among those who had a relaparotomy in contrast to 41 out of
791 (5%) among those without. The 30-day readmission rate
was 115 out of 930 (12%).
Regional activity and outcomes
Procedure demographics stratified by treating RHA are presented
in Table 3, and mortality and relaparotomy rates for each region
are shown in Tables 1 and 2, respectively. Mean annual case load
in each region varied largely. There was a significant regional
difference in use of vascular resection, but the rate of performed
multi-visceral resection did not differ between the RHAs. In
multivariable analysis there was no significant difference between
regions in rate of 90-day mortality, but there was a significant
spread in relaparotomy rate.
Population-based use of PD and vascular- and multi-
visceral resection
The national incidence of PD was 3.6 per 100 000 inhabitants
per year for the complete five-year cohort, and increasing
during the study period, see Fig. 3. Table 3 presents regional
population-based incidences of the procedure and use of
vascular and multi-visceral resection. During the five year
study period only eighteen patients (2%) had their procedure
performed outside their residing RHA, the majority being
referrals to RHA South-East. When the eighteen guest patients
were grouped within their geographical home RHA popula-
tion, there was no difference in age- and gender adjusted
incidence of PD between the populations of the four
geographic regions. The rate of multi-visceral resection offered
to the inhabitants of the four geographical regions did not
differ. However, there was a significant difference in use of
vascular resection between the regions, where patients living in
RHA South-East who had a PD had a more than two-fold rate















All 930 34 (4)
Age group p = 0.003 p < 0.001
<65 357 (38) 3 (1) ref ref
65–74 379 (41) 17 (5) 5.5 (1.8–23.9) 5.0 (1.6–22.0)
75 194 (21) 14 (7) 9.2 (2.9–40.2) 13.8
(4.2–63.0)
Gender p = 0.003 p = 0.007
all females 434 (47) 7 (2) ref ref
<65 159 (37) 0 (0)
65–74 171 (40) 4 (2)
75 97 (23) 3 (3)
all males 496 (53) 27 (6) 3.5 (1.6–8.8) 3.4 (1.5–9.0)
<65 195 (42) 3 (2)
65–74 191 (41) 13 (6)
75 83 (18) 11 (12)
Vascular
resection
p = 0.968 p = 0.625
no 791 (85) 29 (4) ref ref
yes 139 (15) 5 (4) 0.98 (0.3–2.4) 1.3 (0.4–3.5)
Multi-visceral
resection
p = 0.009 p = 0.054
no 886 (95) 29 (3) ref ref
yes 44 (5) 5 (11) 3.8 (1.3–9.6) 3.4 (0.9–9.0)
Relaparotomy p < 0.001 p < 0.001
no 799 (86) 18 (2) ref ref
yes 131 (14) 16 (12) 6.0 (3.0–12.2) 5.9 (2.7–12.8)
Treating RHA p = 0.816 p = 0.561
South-East 513 (55) 18 (4) ref ref
West 197 (21) 9 (5) 1.3 (0.6–3.0) 0.7 (0.3–1.8)
Central 136 (15) 7 (5) 1.5 (0.6–3.6) 1.7 (0.6–4.2)
North 84 (9) 0 (0) 0 (0–0.4) 0 (0–0.4)
a Predictors included in multivariable logistic regression model: Age,
gender, vascular resection, multi-visceral resection, Charlson Comor-
bidity Index, regional health authority (RHA) and relaparotomy.
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of concomitant vascular resection when compared to the in-
habitants of RHA West.
Discussion
This complete and unselected national cohort demonstrates low
mortality rates across all regions. There was no disparity in use of
PD between the regional populations despite a variation in
procedure volume. The contemporary results and practice of PD
in Norway are reassuring when compared to other recent
population-based reports,1,3,11 and the mortality rate is even in
line with publications from expert centres.8,9 The follow-up in
this study includes treatment given in any transfer or re-
admitting hospital and deaths occurring outside hospitals. The
follow-up extends in time beyond the more commonly evaluated
in-hospital data. This further supports the finding of an
acceptable level of short-term complications following PD
achieved within the Norwegian model of centralized pancreatic
surgery, as practiced today.
An evaluation of the short-term mortality after pancreatic
resections in France from 2007 to 2012 reported a 90-day mor-
tality rate after PD of 9% and described a national practice with a
low degree of centralization of pancreatic surgery.1 Likewise, a
recent German national cohort with volume-outcome analysis
reported an in-hospital mortality after major pancreatic resec-
tion ranging from 13% in very-low volume centres to 6% in very
high volume centres.3 Authors of both publications advocated a
further centralization of pancreatic surgery. An analysis from the
National Cancer Database covering 70% of pancreatic resections
in U.S. from 2007 to 2010 reported a 90-day mortality rate from
major pancreatic resections of more than 8%, and also confirms
a volume–outcome relationship.24 In the other range of the
scale, the Dutch Pancreatic Study group reported an in-hospital
mortality rate of 4% for 2014-20152, and an evaluation of all PDs
performed in Japan between 2007 and 2010 revealed an in-
hospital mortality rate of 3% with a significant volume-
outcome correlation.11 In comparison, the in-hospital mortal-
ity rate in this complete, national cohort was even lower (2%),
and also included deaths occurring during transfer stays.
The reasons for the low mortality rates in this cohort, besides
centralization of pancreatic surgery, are not obvious. A restrictive
practice in selection of candidates for surgery could in theory
influence on the beneficial outcomes in Norway, but there are
few, if any, indications of this. Concomitant multi-visceral
resection has previously been shown to increase morbidity and
mortality after PD,25,26 and was a significant predictor of both
relaparotomy and mortality also in the current study. Few other
population-based studies reports rate of concomitant multi-
Figure 2 a–d: Stratified mortality rates the first 180 days after surgery. Stratification by gender, age group, relaparotomy and Regional Health
Authority where treated. Gender, age group and having a relaparotomy were all significant independent predictors of mortality in multivariable
analysis, whereas Regional Health Authority was not (Table 1)
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visceral resection. The rate of multi-visceral resection in this
cohort (5%) was higher than in an analysis of more than 9900
PDs from the US NSQIP database reporting a rate of 3%, despite
that this study included resections of kidneys and adrenal glands
in their definition.25 The reported rates of multi-visceral re-
sections performed in referral centres treating highly selected
patients with advanced disease are much higher,26 but these
cannot serve as a direct comparison to a national, unselected
cohort. Vascular resection did not significantly predict mortality
or relaparotomy in the current cohort, despite of minor re-
sections (e.g. simple venoraphy) being omitted in the definition.
This is in contrast to both a recent meta-analysis on the benefits
of synchronous vein resection,27 and a recent report from a
Norwegian high-volume centre,28 where both studies found









All 930 131 (14)
Age group p = 0.674 p = 0.689
<65 357 (38) 47 (13) ref ref
65–74 379 (41) 58 (15) 1.2 (0.8–1.8) 1.2 (0.8–1.8)
75 194 (21) 26 (13) 1.0 (0.6–1.7) 1.1 (0.6–1.8)
Gender p = 0.001 p = 0.001
female 434 (47) 44 (10) ref ref
male 496 (53) 87 (18) 1.9 (1.3–2.8) 1.9 (1.3–2.9)
Vascular resection p = 0.523 p = 0.304
no 791 (85) 109 (14) ref ref
yes 139 (15) 22 (16) 1.2 (0.7–1.9) 1.3 (0.8–2.2)
Multi-visceral resection p = 0.001 p < 0.001
no 886 (95) 117 (13) ref ref
yes 44 (5) 14 (32) 3.1 (1.5–5.8) 3.2 (1.6–6.3)
Treating RHA p = 0.055 p = 0.034
South-East 513 (55) 66 (13) ref ref
West 197 (21) 35 (18) 1.5 (0.9–2.3) 1.5 (0.9–2.4)
Central 136 (15) 13 (10) 0.7 (0.4–1.3) 0.7 (0.4–1.3)
North 84 (9) 17 (20) 1.7 (1.0–3.1) 1.8 (1.0–3.3)
a Predictors included in multivariable logistic regression model: Age, gender, vascular resection, multi-visceral resection, regional health authority
(RHA) and Charlson Comorbidity Index.
Table 3 Volume and practice stratified by regional health authority
National RHA South-East RHA West RHA Central RHA North Statistical comparison
Treating regional health authority
Procedure volume:
Number of resections, (mean, annual) 930 (186) 513 (103) 197 (39) 136 (27) 84 (17) n.a.
Vascular resection, n (%) 139 (15) 102 (20) 14 (7) 15 (11) 8 (10) p < 0.001
Multi-visceral resection, n (%) 44 (5) 25 (5) 10 (5) 7 (5) 2 (3) p = 0.782
Residing regional health authoritya
Procedure incidence (per 105 inhabitants
per year)
3.6 3.6 3.6 3.8 3.4 p = 0.929
Vascular resection,
n (%)
139 (15) 97 (19) 15
(8)
16 (12) 11 (12) p = 0.021
Multi-visceral
resection, n (%)
44 (5) 23 (5) 10 (5) 7 (5) 4 (4) p = 0.968
P-values lower than 0.05 are shown in bold.
a All patients are grouped within their geographical home RHA (eighteen patients were operated outside their residing region). The regional in-
cidences are adjusted for age and gender composition in the regional populations.
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higher complication rates after synchronous venous resection.
Few reports of rate of vascular resection in a complete population
exist to date. Two recent analyses from the US NSQIP database
used a similar definition and methodology to the current study,
and reported equal,22 or lower,29 rates of vascular resections.
Considering that the current cohort also included resections for
benign or premalignant disease, both multi-visceral and vascular
resections were quite frequent. More than one fifth of patients in
this study were 75 years or older when they had their PD
performed. The proportion of elderly patients in the current
study is in line with or higher than other population-based re-
ports,1–3 which rules out selection by age as a potential bias.
Reports evaluating over-all procedure incidence in complete
populations are scarce. The annual incidence of PD in France
between 2007 and 2012 was lower than in the current cohort (5.8
pancreatic resections per 100 000 inhabitants of which 57%
patients underwent PD equals 3.3 patients undergoing PD per
100,000 inhabitants).1 A recent international evaluation of na-
tional resection rates for patients with malignancy of the
pancreas places Norway in the lower end of the scale,30 but there
are methodological issues pertaining to the way non-operated
cancer patients were identified and it is the authors’ belief the
results should be interpreted with caution. Over-all, there are no
good data to suggest that the contemporary PD incidence rate or
use of vascular resection or multi-visceral resection techniques in
the Norwegian population is lower than what is reported from
other comparable cohorts. Hence, there would not appear to be
any evidence that the favourable short-term outcomes in Norway
are due to a conservative selection practice for patients to un-
dergo PD.
Male gender was found to a predictor of both relaparotomy
(two-fold increase) and mortality (more than three-fold in-
crease). While several earlier reports have also reported males to
have higher rates of postoperative complications,31–33 and
mortality,24 after PD, robust explanations have not been
presented. The excess morbidity and mortality risk for especially
older males should nevertheless be recognized and taken into
account in the process of selecting candidates for surgery.
There was a large variation in mean annual PD case load be-
tween the four regions, ranging from a mean of 17 (low-to-
medium volume centre) to 103 procedures (high-volume
centre). Despite the volume variation, all regions had low mor-
tality rates with no significant disparities. There was, however, a
significant variation in rate of relaparotomy. The region with the
highest relaparotomy rate experienced no deaths within 90 days,
and conversely the region with the fewest relaparotomies had the
highest 90-day mortality rate of all regions (5%). This may reflect
different in-centre approaches to postoperative adverse advents
(e.g. attitude towards relaparotomy for moderate anastomotic
leaks).34,35 The observed a-LoS in the four regions did not
correspond to the regional pattern in mortality or relaparotomy
rates, and may be due to different perioperative care regimens
and use of enhanced-recovery principles.36 Nationwide practice
is likely to be become more uniform in the years to come due to a
common perioperative registry and increased cooperation, see
below.
The observed equity in population based incidence of resec-
tion between the independent regions points to a uniform
practice in terms of evaluation of resectability and selection for
surgery. As the regional organizational model neutralizes dif-
ferences in patient or tumour factors, the variation between re-
gions in rate of vascular resection is probably due to divergent in-
centre practice and attitudes towards the theoretical gains from
vascular resection.
Centralization of HPB surgery in Norway started almost two
decades ago. Still, in a sparsely inhabited country with large
geographical distances, the size of the catchment areas of the
HPB-units varies between 0.5 million and 2.5 million in-
habitants. This study was a comparison of outcomes between a
low number of single centres with variable annual case load and
the performance of each centre may interfere regardless of
volume. The regional results should therefore be used with
caution in a debate of volume-outcome causality. However, the
well-documented volume–outcome relationship for post-
operative mortality was not confirmed in the current study. All
five HPB-centres are academic teaching hospitals, which has
been shown to provide superior outcomes after pancreatic sur-
gery.37,38 Notably, all the centres perform all other types of HPB
surgery (except transplants) for their respective populations, and
Figure 3 Trend in national incidence of pancreatoduodenectomy
2012–2016. Resections per 100,000 inhabitants per year is shown in
continuous black line, with 95% confidence interval in grey. Regional
incidences (marked with “o”) are adjusted for age- and gender differ-
ences in the respective populations. There was a significant increase in
the national incidence of pancreatoduodenectomy during the study
period, p = 0.006
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the total annual volume of major HPB resections per centre is at
least four-fold that of their PD volume. The uniformity in
practice and outcomes may also be influenced by a close aca-
demic cooperation in national resource groups. The discrepancy
in rate of vascular resection offered to the regional populations
will be further examined in prospectively gathered data that will
be available from the Norwegian gastrointestinal resection reg-
istry (NoRGast) in the near future.39 NoRGast will also provide
more detailed data on patient comorbidity and re-interventions.
There are some limitations to this study that deserve to be
mentioned. When addressing administrative data, the data
quality depends on accuracy and completeness of coding.
Diagnostic codes are susceptible to differences in coding practice,
and therefore these were only used for CCI. The diagnostic codes
used for pancreatic malignancy might also have been used for
only suspected malignancy, and malignancy was therefore not
analysed as a predictor of outcomes. Secondly, data for patient
weight and height or granular information on the disease (e.g.
histological type, size, TNM stage) or the pancreatic gland (e.g.
texture, duct diameter) were not available for further risk strat-
ification. Procedure codes denoting vascular resection were also
crude, and did not allow for further grouping into arterial or
venous resection. The lack in precision in coding for cause of
relaparotomy did not allow for further exploration of the cause
for reoperation. Data for radiological or endoscopic re-
intervention for anastomotic leaks or bleeding were not avail-
able through the NPR.
One of the strengths of this study is the design that allows
capture of complete patient journeys within the NPR. This
extended follow-up, which included post-discharge data, sub-
stantially raised both mortality and relaparotomy rates as well as
length-of-stay compared to in-hospital data alone. A significant
proportion of deaths within 90 days occurred after primary
discharge to home (from either index or transfer receiving unit),
and almost one in five relaparotomies were done outside the
index hospital. The length-of-stay increased more than fifty per
cent when transfer stays and readmissions were included.21
When comparing the results from this cohort to other studies
reporting solely in-hospital data these disparities in follow-up
should be taken into account.
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Background: Centralization of pancreatic surgery is currently called for owing to superior outcomes
in higher-volume centres. Conversely, organizational and patient concerns speak for a moderation in
centralization. Consensus on the optimal balance has not yet been reached. This observational study
presents a volume–outcome analysis of a complete national cohort in a health system with long-standing
centralization.
Methods: Data for all pancreatoduodenectomies in Norway in 2015 and 2016 were identified through a
national quality registry and completed through electronic patient journals. Hospitals were dichotomized
(high-volume (40 or more procedures/year) or medium–low-volume).
Results: Some 394 procedures were performed (201 in high-volume and 193 in medium–low-volume
units). Major postoperative complications occurred in 125 patients (31⋅7 per cent). A clinically relevant
postoperative pancreatic fistula occurred in 66 patients (16⋅8 per cent). Some 17 patients (4⋅3 per cent)
died within 90 days, and the failure-to-rescue rate was 13⋅6 per cent (17 of 125 patients). In multivariable
comparison with the high-volume centre, medium–low-volume units had similar overall complication
rates, lower 90-day mortality (odds ratio 0⋅24, 95 per cent c.i. 0⋅07 to 0⋅82) and no tendency for a higher
failure-to-rescue rate.
Conclusion: Centralization beyond medium volume will probably not improve on 90-day mortality or
failure-to-rescue rates after pancreatoduodenectomy.
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Introduction
A volume–outcome effect on mortality after pancreato-
duodenectomy (PD) has been demonstrated repeatedly,
with lower short-term mortality rates in high-volume
centres1–5. The failure to prevent death in patients suffer-
ing from major postoperative morbidity (failure-to-rescue
(FTR)) has been proposed as a mechanism behind the
volume–outcome effect on mortality that is more impor-
tant than the occurrence of postoperative complications6,7.
Timely recognition and optimally sequenced treatment of
complications after PD is a complex matter and requires a
multidisciplinary approach8,9. A higher unit caseload nec-
essarily reflects greater experience in the handling of com-
plications. Academic teaching status of the treating hospital
has also been proposed to influence FTR7.
Covering a population of just 5⋅3 million inhabitants over
a vast geographical area, pancreatic surgery in Norway has
been restricted to only five hepatopancreatobiliary (HPB)
units for more than a decade10–12. All are academic teaching
hospitals with 24-h interventional radiology and endoscopy
services available, and highly resourced ICUs. Although
centralized, catchment areas vary substantially between
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the units, from high- to medium-volume combined HPB
and upper gastrointestinal units covering 0⋅5–1⋅0 million
inhabitants each, to a single very high-volume dedicated
HPB unit serving an uptake population of more than
2⋅6 million. The government funds the universal health-
care coverage, and there are no private institutions for
resectional surgery.
A previous nationwide analysis11 using administrative
data documented a low contemporary 90-day mortality rate
after PD in Norway, and negligible cross-regional patient
drift. There were similar regional population-based inci-
dences of the procedure and equal mortality rates among
patients treated at the respective units, but variation in
relaparotomy rates and use of vascular reconstruction was
demonstrated11. A significant proportion of relaparotomies
within 30 days (1 in 5) and deaths within 90 days (4 in 10)
occurred after first discharge from hospital11. The cen-
tralization of surgery within a single-payer health system
relies on patients being transferred back to general hos-
pitals for parts of the postoperative phase and follow-up.
Although still under the auspices of the operating (index)
unit, these transfers reduce the patients’ organizational
and geographical proximity to the index surgical unit in
the subacute recovery phase, where postoperative adverse
events may still develop. This is an inherent consequence
of centralization in all but the most densely populated
countries.
This study assessed overall and procedure-specific out-
comes in a complete national cohort of patients undergo-
ing PD, and investigated for a volume–outcome effect in a
country with longstanding centralization but a large varia-
tion in unit volume. The aim of the analysis was to examine
a potential benefit from further centralization.
Methods
All patients registered in the Norwegian Registry for Gas-
trointestinal and HPB Surgery (NoRGast) have given
written informed consent13. In addition, the project was
granted allowance from the Norwegian Directorate of
Health for additional access to electronic patient journal
(EPJ) data. Approval of alignment of the multicentre data
was given by the Data Protection Authority of Norway (ref-
erence number 17/33320-2).
Study design
This was an observational cohort study of complete nation-
wide data in a universal health coverage system. The
STROBE guidelines14 for reporting observational studies
were adhered to, where applicable.
Accrual of data
NoRGast is a procedure-driven national quality registry
with prospective gathering of core data for case mix and
postoperative complications13. All five Norwegian HPB
units contribute data to NoRGast. Data for all registered
pancreatoduodenectomies performed between January
2015 and December 2016 were retrieved from the NoR-
Gast database. Data from NoRGast were cross-checked
at a patient level by performing an identical search for
the same procedure codes in the local EPJs for each HPB
unit, and data for missing patients were included. In addi-
tion, procedure-specific variables and complications not
available in NoRGast (preoperative biliary drainage, dura-
tion of procedure, intraoperative haemorrhage, grade of
postoperative pancreatic fistula (POPF), grade of postpan-
createctomy haemorrhage (PPH) and histopathology data)
were registered manually from the EPJ for all patients by
a local HPB surgeon. Three of the four healthcare regions
have a shared regional EPJ, allowing direct access to
patient data for any transfer stays or readmissions outside
the index unit; this ensures data quality for complications
occurring after the index stay. In the one region where
regional EPJ access was not available, discharge reports
from transfer stays or readmissions were collected and
evaluated. Date of death is available automatically in the




Severe cardiac disease (New York Heart Association class
above 2 or severe arrhythmia) and pulmonary disease
(forced expiratory volume in 1 s less than 50 per cent and/or
vital capacity below 60 per cent) were defined in accordance
with the modified form of the Estimation of Physiologic
Ability and Surgical Stress (E-PASS) system15. Diabetes
mellitus was defined by preoperative use of any antidiabetic
medication, administered either subcutaneously or orally.
Procedure details and postoperative complications
Any complication graded as 3 or above in the Accordion
system16 was considered a major complication. Briefly,
Accordion grade 3 refers to percutaneous or endoscopic
reintervention with or without general anaesthesia; Accor-
dion 4 refers to relaparotomy or single-organ failure (SOF);
Accordion 5 refers to relaparotomy and SOF, or multi-
ple organ failure alone; and Accordion 6 refers to death.
POPF17, PPH18 and venous resection19 were scored in
accordance with proposed guidelines from the Interna-
tional Study Group of Pancreatic Surgery.
© 2020 The Authors. www.bjsopen.com BJS Open
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Table 1 Patient demographics




(n = 193) Unit range# P††
Age (years)* 67⋅5 (60–73) 68 (61⋅5–74) 67 (58–72) 66–67⋅5 0⋅364‡‡
BMI (kg/m2)* 24⋅5 (21⋅9–26⋅9) 24⋅1 (21⋅7–26⋅7) 24⋅6 (22⋅0–27⋅1) 24⋅2–25⋅5 0⋅271‡‡
Albumin (g/l)* 40⋅0 (36⋅0–43⋅0) 40⋅0 (35⋅5–43⋅0) 40⋅0 (36⋅0–43⋅0) 36⋅0–43⋅0 0⋅584‡‡
Weight loss† n = 315 n = 149 n = 166
Any 231 (73⋅3) 117 (78⋅5) 114 (68⋅7) (62⋅5–71⋅7) 0⋅064
>5% 185 (58⋅7) 101 (67⋅8) 84 (50⋅6)
>10% 90 (28⋅6) 62 (41⋅6) 28 (16⋅9)
Diabetes mellitus‡ 68 (17⋅3) 36 (17⋅9) 32 (16⋅6) (6⋅3–22⋅6) 0⋅829
Neoadjuvant chemotherapy 22 (5⋅6) 11 (5⋅5) 11 (5⋅7) (0–12⋅9) 0⋅922
Severe pulmonary disease§ 15 (3⋅8) 3 (1⋅5) 12 (6⋅2) (0–18⋅8) 0⋅014
Severe cardiac disease¶ 23 (5⋅8) 11 (5⋅5) 12 (6⋅2) (0–11⋅3) 0⋅753
Preoperative drainage 150 (38⋅1) 88 (43⋅8) 62 (32⋅1) (25⋅8–37⋅1) 0⋅017
ERCP 134 (34⋅0) 88 (43⋅8) 46 (23⋅8) (17⋅8–31⋅3)
PTC 16 (4⋅1) 0 (0) 16 (8⋅3) (0–15⋅6)
ECOG score 0⋅083
0 288 (73⋅1) 157 (78⋅1) 131 (67⋅9) (62⋅2–71⋅4)
1 95 (24⋅1) 39 (19⋅4) 56 (29⋅0) (25⋅7–37⋅5)
>1 11 (2⋅8) 5 (2⋅5) 6 (3⋅1) (0–4⋅4)
ASA grade 0⋅487
I–II 216 (55⋅0) 106 (53⋅0) 110 (57⋅0) (46⋅8–75⋅0)
≥ III 177 (45⋅0) 94 (47⋅0) 83 (43⋅0) (25⋅0–53⋅2)
Histopathology (extracted specimens) n = 393 n = 201 n = 192** 0⋅072
Any malignancy 324 (82⋅4) 173 (86⋅1) 151 (78⋅6) (67⋅1–93⋅8)
PDAC 161 (41⋅0) 83 (41⋅3) 78 (40⋅6)
Common bile duct cancer 58 (14⋅8) 36 (17⋅9) 22 (11⋅5)
Duodenal cancer 36 (9⋅2) 25 (12⋅4) 11 (5⋅7)
Ampullary/papillary cancer 30 (7⋅6) 9 (4⋅5) 21 (10⋅9)
Other 39 (9⋅9) 20 (10⋅0) 19 (9⋅9)
Any benign disease 69 (17⋅6) 28 (13⋅9) 41 (21⋅4) (6⋅3–32⋅9)
IPMN without adenocarcinoma 25 (6⋅4) 5 (2⋅5) 20 (10⋅4)
Pancreatitis 11 (2⋅8) 9 (4⋅5) 2 (1⋅0)
Other 33 (8⋅4) 14 (7⋅0) 19 (9⋅9)
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). †Patient-reported weight loss in 6 months before surgery.
‡Defined by use of any antidiabetic medication, administered subcutaneously or orally. §Forced expiratory volume in 1 s less than 50 per cent or vital
capacity less than 60 per cent. ¶New York Heart Association class 3–4 or arrhythmia requiring mechanical support. #Within medium–low volume category.
**One patient died during surgery. ERCP, endoscopic retrograde cholangiopancreatography; PTC, percutaneous transhepatic cholangiography; ECOG,
Eastern Co-operative Oncology Group; PDAC, pancreatic ductal adenocarcinoma; IPMN, intraductal papillary mucinous neoplasm. ††χ2 test (high versus
medium–low volume, dichotomized), except ‡‡Kruskal–Wallis test.
Failure-to-rescue
FTR was defined as any death within 90 days in patients
with any major complication (Accordion grade 3 or above).
Deaths with no recorded preceding major complication
were included, in accordance with the original20 and
recommended21 definition.
Hospital volume
Hospital units were dichotomized according to procedure
volume, and defined as high volume for 40 or more pro-
cedures per year (1 unit) or as medium–low volume for
fewer than 40 procedures per year (4 units). Others3,5,6,22–24
have suggested this cut-off, and it allowed for meaningful
comparison within the Norwegian setting. Length of stay
was defined conventionally as the number of postoperative
nights spent at the hospital after the procedure, omitting
any transfer and/or readmission stays.
Primary outcomes
The primary outcomes of the study were incidence and
type of major postoperative complications, overall 90-day
© 2020 The Authors. www.bjsopen.com BJS Open
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Table 2 Procedure characteristics




(n = 193) Unit range‡ (16–70) P§
Estimated blood loss (ml) (n = 352)* 350 (700–1200) 200 (100–500) 490 (300–490) 300–1165 <0⋅001¶
Duration of surgery (min) (n = 383)* 322 (262–386) 341 (283–418) 300 (240–300) 240–431 <0⋅001¶
Without VR 308⋅5 (252–359) 323 (274–373) 300 (240–343) 240–354 <0⋅001¶
With VR 420 (355–454) 420 (369–454) 393 (337–465) 240–431 0⋅415¶
Classical PD† 206 (52⋅3) 60 (29⋅9) 146 (75⋅6) (12⋅5–100) <0⋅001
Peroperative blood transfusion 76 of 391 (19⋅4) 38 of 198 (19⋅2) 38 (19⋅7) (10⋅0–35⋅5) 0⋅901
Any vascular resection 70 (17⋅8) 50 (24⋅9) 20 (10⋅4) (5⋅7–17⋅7) <0⋅001
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). †Classical pancreatoduodenectomy (PD) (Whipple procedure);
all others were pylorus-preserving pancreatoduodenectomies. ‡Within medium–low volume group; the lowest case volume was 16 and the highest was 70.
VR, vascular resection. §χ2 test (high versus medium–low volume, dichotomized), except ¶Kruskal–Wallis test.
Table 3 Short-term outcomes




(n = 193) Unit range† P‡
Any major complication 125 (31⋅7) 57 (28⋅4) 68 (35⋅2) (31⋅2–42⋅2) 0⋅143
Accordion 3 46 (11⋅7) 21 (10⋅4) 25 (13⋅0) 0⋅436¶
Accordion 4 51 (12⋅9) 22 (10⋅9) 29 (15⋅0)
Accordion 5 15 (3⋅8) 6 (3⋅0) 9 (4⋅7)
Accordion 6 (30-day mortality) 10 (2⋅5) 8 (4⋅0) 5 (2⋅6)
POPF n = 393 n = 201 n = 192
None or biochemical leak 327 (83⋅2) 180 (89⋅6) 147 (76⋅6) (71⋅4–83⋅6)
Grade B 41 (10⋅4) 13 (6⋅5) 28 (14⋅6) (6⋅3–17⋅1) <0⋅001#
Grade C 25 (6⋅4) 8 (4⋅0) 17 (8⋅9) (3⋅3–12⋅5)
PPH n = 393 n = 201 n = 192
None or grade A 349 (88⋅8) 177 (88⋅1) 172 (89⋅6) (85⋅7–100) 0⋅741#
Grade B 22 (5⋅6) 10 (5⋅0) 12 (6⋅3) (0–8⋅2)
Grade C 22 (5⋅6) 14 (7⋅0) 8 (4⋅2) (0–7⋅1)
Relaparotomy 71 (18⋅1) 32 (15⋅9) 39 (20⋅3) (8⋅2–28⋅6) 0⋅258
Haemorrhage 23 (5⋅9) 13 (6⋅5) 10 (5⋅2) 0⋅026¶
Pancreatic leak 17 (4⋅3) 5 (2⋅5) 12 (6⋅3)
Biliary leak 8 (2⋅0) 1 (0⋅5) 7 (3⋅6)
Wound dehiscence 4 (1⋅0) 4 (2⋅0) 0 (0)
Other 19 (4⋅8) 9 (4⋅5) 10 (5⋅2)
90-day mortality 17 (4⋅3) 11 (5⋅5) 6 (3⋅1) (0–6⋅3) 0⋅323
Length of stay at index hospital (days) (n = 391)* 9 (7–16) 7 (6–11) 14 (9–21) 7–18 <0⋅001§
No major complication* 8 (6–13) 7 (6–8) 13 (8–15) 7–15 <0⋅001§
Any major complication* 18 (11–29) 14 (10–30) 21 (13–28) 13–24 0⋅129§
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.) with median unit range. †Within medium–low volume
group. POPF, postoperative pancreatic fistula; PPH, postpancreatectomy haemorrhage. ‡χ2 test (high versus median–low volume, dichotomized), except
§Kruskal–Wallis test; ¶univariable χ2 comparison of Accordion grade or reason for relaparotomy distribution; #univariable χ2 comparison of presence of
clinically relevant POPF or PPH grade B–C.
mortality, and 90-day mortality among patients with major
postoperative complications (FTR).
Statistical analysis
Crude demographics, procedure details, major compli-
cations and histopathology data are presented as median
(i.q.r.) values, or as absolute numbers with percent-
ages. Crude comparison across volume categories was
done using the χ2 test for categorical variables and the
Kruskal–Wallis (non-parametric) test for continuous
variables.
Multivariable logistic regression analyses of the postop-
erative outcomes any major complication, relaparotomy,
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Table 4 Multivariable analysis of predictors of postoperative complications*
Odds ratios
Any major complication Relaparotomy 90-day mortality CR POPF PPH grade B or C
Age (years)
<65 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
65–74 1⋅19 (0⋅73, 1⋅91) 1⋅20 (0⋅68, 2⋅51) 4⋅63 (0⋅87, 24⋅22) 1⋅24 (0⋅69, 2⋅25) 0⋅95 (0⋅47, 1⋅92)
≥75 0⋅60 (0⋅31, 1⋅16) 0⋅57 (0⋅24, 1⋅34) 7⋅66 (1⋅14, 51⋅44) 0⋅62 (0⋅26, 1⋅49) 0⋅58 (0⋅20, 1⋅69)
P 0⋅112 0⋅212 0⋅098 0⋅271 0⋅594
Sex
F 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
M 1⋅21 (0⋅78, 1⋅89) 1⋅23 (0⋅72, 2⋅09) 3⋅69 (1⋅05, 13⋅02) 0⋅97 (0⋅51, 1⋅85) 1⋅77 (0⋅91, 3⋅45)
P 0⋅393 0⋅452 0⋅042 0⋅934 0⋅092
Indication
Any malignancy 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
Benign disease 1⋅75 (0⋅92, 2⋅98) 0⋅82 (0⋅39, 1⋅87) 0⋅41 (0⋅04, 3⋅84) 1⋅96 (0⋅94, 3⋅44) 0⋅86 (0⋅33, 2⋅27)
P 0⋅087 0⋅602 0⋅438 0⋅098 0⋅767
Vascular resection
No 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
Yes 1⋅30 (0⋅72, 2⋅34) 1⋅62 (0⋅84, 2⋅81) 1⋅33 (0⋅30, 5⋅81) 0⋅72 (0⋅30, 1⋅71) 4⋅27 (2⋅20, 8⋅28)
P 0⋅381 0⋅149 0⋅709 0⋅456 <0⋅001
Preoperative biliary drainage
No 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
Yes 0⋅72 (0⋅45, 1⋅16) 0⋅79 (0⋅52, 1⋅64) 0⋅21 (0⋅05, 0⋅86) 0⋅50 (0⋅27, 0⋅92) 0⋅57 (0⋅28, 1⋅15)
P 0⋅178 0⋅781 0⋅030 0⋅025 0⋅117
Peroperative RBC transfusion
No 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
Yes 1⋅68 (0⋅99, 2⋅85) 2⋅12 (1⋅17, 3⋅82) 1⋅78 (0⋅49, 6⋅33) 1⋅28 (0⋅64, 2⋅57) 1⋅68 (0⋅81, 3⋅49)
P 0⋅053 0⋅013 0⋅376 0⋅481 0⋅164
Relaparotomy
No 1⋅00 (reference)
Yes 20⋅72 (6⋅03, 71⋅18)
P <0⋅001
Unit volume
High 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
Medium–low 1⋅28 (0⋅82, 1⋅98) 1⋅38 (0⋅82, 2⋅33) 0⋅24 (0⋅07, 0⋅82) 2⋅52 (1⋅43, 4⋅43) 1⋅10 (0⋅55, 2⋅19)
P 0⋅274 0⋅229 0⋅023 0⋅001 0⋅782
Values in parentheses are 95 per cent confidence intervals. *Other potential predictors evaluated in the multivariable logistic regression analysis, but not
found to be significant predictors were BMI, weight loss greater than 10 per cent, albumin, diabetes mellitus, neoadjuvant chemotherapy, severe pulmonary
disease, severe cardiac disease, Eastern Co-operative Oncology Group class above zero, ASA grade above II, duration of surgery and type of procedure.
CR POPF, clinically relevant postoperative pancreatic fistula; PPH, postpancreatectomy haemorrhage; RBC, red blood cell.
clinically relevant (CR) POPF and PPH grade B/C were
performed using a backwards stepwise approach, where
centre volume was included as a predictor. A similar mul-
tivariable model was built to evaluate the predictors of
death after major postoperative complications (FTR). The
regression models were assessed for significant interac-
tions and collinearity. Effect measures from multivariable
analyses are reported as odds ratios (ORs) with 95 per
cent confidence intervals. Level of significance for all final
analyses was set to P < 0⋅050.
IBM SPSS Statistics version 26.0 (IBM, Armonk New
York, USA) was used for all statistical analyses.
Results
A total of 394 patients in Norway had a PD (all open
resections) during the 2-year study period. Mean
annual procedure volume ranged from 101 PDs in the
high-volume centre to 35, 31, 23 and eight PDs respec-
tively (median 27) in the four medium–low-volume
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Table 5 Characteristics of 17 patients who died within 90 days of surgery






M 47 MV None CW, vein resection
type 1
PDAC (R1) Relaparotomy, POPF grade B,
PPH grade C
30 No
M 67 HV None PPPD Pancreatitis Sudden cardiac arrest POD 5 30 No
F 85 HV None PPPD PDAC (R1); extensive SMA
dissection
Diarrhoea, renal failure 30 Yes
M 68 HV None PPPD Duodenal adenocarcinoma Relaparotomy, PPH grade C 30 No
M 76 HV Cardiac
disease
CW Distal CC (R1) Relaparotomy (wound
dehiscence only)
30 No
M 76 MV DM PPPD Other malignancy (R0) Relaparotomy, POPF grade C,
PPH grade C
30 No
F 71 MV None CW Other malignancy (R0) Relaparotomy (wound
dehiscence only)
30 No
F 65 MV DM CW No specimen retrieved Peroperative death from
haemorrhage
30 No
M 69 LV None PPPD Distal CC (R0) Relaparotomy, POPF grade C 30 No
F 70 HV None CW, vein resection
type 3
Distal CC (R0) Relaparotomy, POPF grade C,
PPH grade C
30–90 No
F 71 HV None PPPD, vein
resection type 3
PDAC (R1) Relaparotomy, POPF grade C 30–90 Yes
M 63 HV None CW, vein resection
type 3
PDAC (R1) Infection after initiating
adjuvant chemotherapy
30–90 Yes




Pneumonia, prolonged DGE 30–90 Yes
M 74 HV DM CW Duodenal
adenocarcinoma (R1)
Relaparotomy, POPF grade C,
PPH grade C
30–90 No





M 74 MV None CW PDAC (R0) Relaparotomy, POPF grade C,
PPH grade C
30–90 No
M 71 HV None PPPD Distal CC (RO) Relaparotomy, POPF grade C 30 No
*International Study Group of Pancreatic Surgery classification of vein resection. MV, medium volume; CW, classical Whipple procedure; PDAC, pancre-
atic ductal adenocarcinoma; POPF, postoperative pancreatic fistula; PPH, postpancreatectomy haemorrhage; HV, high volume; PPPD, pylorus-preserving
pancreatoduodenectomy; POD, postoperative day; SMA, superior mesenteric artery; CC, cholangiocarcinoma; DM, diabetes mellitus; LV, low volume;
DGE, delayed gastric emptying.
units. Follow-up at 30 days (complications) and 90 days
(mortality) was complete (394, 100 per cent).
Patient demographics
Baseline patient data are presented in Table 1. The median
age was 67⋅5 (i.q.r. 60–73) years, and 187 (47⋅5 per cent)
of the patients were men. Of 393 extracted specimens
(1 intraoperative death with no retrieved specimen),
malignant disease was confirmed in 324 (82⋅4 per cent).
Pancreatic ductal adenocarcinoma (PDAC) was found
in 161 (49⋅7 per cent) of malignant specimens. Patients
treated in the high-volume centre had a significantly
higher rate of preoperative biliary drainage than those in
the medium–low-volume units (88 of 201 (43⋅8 per cent)
versus 62 of 193 (32⋅1 per cent) respectively; P = 0⋅017),
and a lower rate of severe pulmonary disease (3 of 201
(1⋅5 per cent) versus 12 of 193 (6⋅2 per cent); P = 0⋅014).
There were no other significant differences in patient
characteristics between patients treated in the high- and
medium–low-volume units, including no difference in
proportions of specimens with malignant versus benign
disease.
Procedure characteristics
Procedure characteristics are presented in Table 2. Con-
comitant vascular resection (vein or artery) was done in 70
(17⋅8 per cent) of the operations, and specifically in 54 of
161 (33⋅5 per cent) of resections for PDAC. Patients treated
in the high-volume centre had significantly lower estimated
blood loss and longer duration of surgery for all procedures
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High-volume centre (n= 201)
Medium–low-volume units combined (n= 193)
Medium-volume unit
Low-volume unit
a Postoperative complications (Accordion grade 3–6); b 90-day mortality; c failure-to-rescue. Multivariable analysis with high volume as reference (odds
ratio (OR) 1⋅00): a OR 1⋅28 (95 per cent c.i. 0⋅82 to 1⋅98), P = 0⋅274; b OR 0⋅24 (0⋅07 to 0⋅82), P = 0⋅023; c OR 0⋅49 (0⋅26 to 1⋅63), P = 0⋅243.
and for PDs without concomitant vascular resection, a
lower rate of classical PD (versus pylorus-preserving PD)
and a higher rate of any vascular resection. Most arterial
resections were performed in the high-volume centre (14
of 16); none of these 16 patients died within 90 days.
Postoperative complications
Crude rates of postoperative complications and univariable
comparison between volume categories are presented in
Table 3. Major complications occurred in 125 patients (31⋅7
per cent). Results from multivariable analyses are presented
in Table 4. When analysing centre volume category as a
predictor of postoperative outcomes, medium–low volume
was a predictor of lower mortality within 90 days (OR 0⋅24,
95 per cent c.i. 0⋅07 to 0⋅82) but of a higher rate of CR
POPF (OR 2⋅52, 1⋅43 to 4⋅43). Medium–low-volume unit
did not independently predict occurrence of any major
complication, relaparotomy or PPH grade B/C. Impor-
tantly, variation in the use of vascular resection between
the volume categories was adjusted for.
Failure-to-rescue
Detailed patient data for all patients who died within
90 days are shown in Table 5. All but four of the patients
who died within 90 days experienced at least one major
surgical complication within 30 days: CR POPF (8 of 17),
PPH grade B/C (6 of 17) and relaparotomy (12 of 17). The
rate of FTR after any major complication was 13⋅6 per cent
(17 of 125). The mortality rate after any relaparotomy and
PPH grade B/C was 12 of 71 (17 per cent) and 7 of 44 (16
per cent). Overall mortality after CR POPF was eight of
66 (12 per cent), with separate mortality rates after POPF
grade B and C of one of 41 (2 per cent) and seven of 25 (28
per cent) respectively.
The FTR rate in the high-volume centre was 11 of 57
(19 per cent), compared with six of 68 (9 per cent) in
medium–low-volume units (Fig. 1). In multivariable analy-
sis assessing the same predictors as for postoperative com-
plications (Table 4), medium–low unit volume was not an
independent predictor of higher FTR (OR 0⋅49, 95 per
cent c.i. 0⋅26 to 1⋅63; P = 0⋅243).
Discussion
These data indicate that results similar to those in
high-volume expert centres may be obtained within a
single-payer PD service practising a moderate degree
of centralization. The sole high-volume centre had out-
comes on a par with those from internationally renowned
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high-volume centres24, but, importantly, so had the three
medium-volume centres with 20–40 procedures per year.
This suggests that a balance between beneficial short-term
clinical outcomes and organizational concerns may have
been obtained with this caseload.
The national outcomes in terms of rates of any major
complication, POPF, PPH and FTR are comparable to the
results and benchmarks cut-off values established from an
international cohort of 23 high-volume expert centres25.
Of note, whereas their benchmark values25 were based on a
subset of low-risk patients, excluding more than 50 per cent
of their total patient cohort, the present study included 100
per cent of patients operated on across Norway during the
study period (a true population-based cohort).
As shown previously11, national 30- and 90-day mortality
rates were low in comparison with contemporary cohorts
from Germany, France and the USA, and in line with rates
reported from Sweden and the Netherlands1,2,26–28. Rates
of any major complication, CR POPF and PPH grade
C were equal to coeval cohorts from the USA, Nether-
lands and Germany22,29,30. The relaparotomy rate in the
present cohort (18⋅1 per cent) was similar to, or some-
what higher than, that reported from other studies22,30,31.
Compared with similar population-based cohorts29,30, the
median operating time of 322 min was short and median
estimated blood loss (350 ml) was low.
The national rate of FTR after PD of 13⋅6 per cent
in the present cohort is in line with recent rates of 9
per cent reported from the US American College of Sur-
geons National Surgical Quality Improvement Program
database32 and 14⋅3 per cent in the Dutch Pancreatic Can-
cer Audit6. Importantly, the existing diversity in defini-
tions of major postoperative morbidity used to calculate
FTR rates hampers a direct comparison between studies.
A Dutch study33 of the management of POPF used a def-
inition similar to that employed in the present study, and
reported an in-hospital mortality rate after CR POPF of
17⋅8 per cent. In comparison, the present cohort demon-
strated a 90-day mortality rate after CR POPF of 12
per cent.
The national mortality rate after PD achieved within
the current organizational model in Norway is very low,
and the improvement potential in terms of short-term
mortality is not obvious. A root-cause analysis of mor-
tality within 90 days after major pancreatectomy by
Vollmer and colleagues34 found pancreatic fistula or other
surgery-related cause as the main reason for death in 13⋅8
and 26⋅6 per cent respectively, and the relaparotomy rate
among the patients who died was 35⋅3 per cent. In contrast,
the present cohort demonstrated that 14 of 17 patients who
died within 90 days experienced surgical complications,
and almost three in four had a relaparotomy within 30 days
of the index operation. Despite the already reassuring
national mortality rate, a potential for further decline may
lie in a future focus on lowering the incidence, and timely
and optimal handling, of surgical complications.
The medium–low-volume units had similar outcomes
to those in the high-volume centre. This stands in con-
trast to a perceived more linear volume–outcome effect,
as suggested in several earlier reports1,5,31. Moreover, and
supporting the present observations, other reports6,24,35
have also failed to show superior outcomes in high-volume
units in comparison with medium-volume units. When
assessing the literature of the volume–outcome relation-
ship, one must be aware of the various definitions used for
volume categories. Although the present analysis used 40
procedures a year as the cut-off for high volume, as have
others5,6,22, several other publications4,36 have defined high
volume as more than 20 procedures a year. According to
this definition, the vast majority (95⋅9 per cent) of the pro-
cedures constituting the present cohort were performed
in high-volume units, and hence the broadly accepted
volume–outcome relationship would serve as an explana-
tory factor for the beneficial results. The single low-volume
unit represents an outlier in the medium–low-volume
category. It was included in the analyses in order to
present a complete national cohort. The absolute num-
bers of resections performed in this unit (16 over 2 years)
did not allow for statistical comparison in a separate
low-volume category, but the degree of divergence in out-
comes (Fig. 1) was deemed too low to skew the results in
the medium–low-volume category combined.
The equity in key short-term outcome metrics observed
across the large span in unit volume in the present cohort
raises the question of whether other organizational fac-
tors can compensate for a moderate case load (20–40 pro-
cedures a year). A ceiling effect of the volume–outcome
benefits may be reached within this interval, and several
mechanisms may contribute to this. All five units perform-
ing pancreatic resections are academic centres, which have
been shown previously to contribute more to lower mor-
tality and FTR rates than unit caseload itself7,37,38. Fur-
ther, all four medium–low-volume units annually perform
other HPB and upper gastrointestinal resections in num-
bers at least fourfold of their caseload for PD. This fre-
quent exposure to anatomically related surgery has been
proposed to contribute to improved outcomes after PD,
and even to compensate for a lower volume of pancre-
atic surgery39. The lower length of stay in the index unit
(before transfer) in the high-volume centre, combined
with higher 90-day mortality and (although statistically
non-significant) almost twofold higher FTR rate, is also
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of interest. It raises the question of whether follow-up in
geographical and organizational vicinity to the index unit
and operating surgeon, which is to a larger extent practised
by the medium–low-volume units, is beneficial for optimal
and timely recognition and handling of complications. Of
note, the higher mortality rate in the high-volume centre
found in the present cohort must be interpreted with cau-
tion, as the authors demonstrated previously11, in a larger
and partly overlapping cohort, that there was no difference
in 90- and 180-day mortality between the regional health
authorities in Norway.
From the patient’s perspective, clinical outcomes after
surgery are paramount, and outscore reasonable increases
in longer travel distances to the treating hospital unit40–42.
However, continuity in care during preoperative workup,
surgery and long-term postoperative follow-up, as well as
accessibility to specialized healthcare providers for contact
and information, also weighs heavily41, and is perhaps
easier to obtain within an organizational model with a
moderate level of centralization.
Several limitations deserve to be acknowledged. First, the
present cohort is not large and, owing to a small abso-
lute number of rare events, suffers from the risk of being
underpowered. Second, as the analyses classified only one
unit in the high-volume category, transferability to other
high-volume units in general is weakened. Data on gland
texture and duct diameter were not available, and a fistula
risk score could not be included as a co-variable. However,
as shown previously11, both the identical population-based
incidence of PD across the nation and the negligible
regional patient drift, together with the similar propor-
tions of malignant versus benign specimens found in the two
unit-volume categories, make a large disparity in case mix
and fistula risk score highly unlikely.
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